<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for prophylaxis of vestibular migraine - Webster, KE - 2023 | Cochrane Library</title> <meta content="Pharmacological interventions for prophylaxis of vestibular migraine - Webster, KE - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015187.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for prophylaxis of vestibular migraine - Webster, KE - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015187.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015187.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for prophylaxis of vestibular migraine" name="citation_title"/> <meta content="Katie E Webster" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="katie.webster@doctors.org.uk" name="citation_author_email"/> <meta content="Afrose Dor&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Kevin Galbraith" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Luma Haj Kassem&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Aleppo University Hospital" name="citation_author_institution"/> <meta content="Natasha A Harrington-Benton" name="citation_author"/> <meta content="Ménière's Society" name="citation_author_institution"/> <meta content="Owen Judd" name="citation_author"/> <meta content="University Hospitals of Derby and Burton NHS Foundation Trust" name="citation_author_institution"/> <meta content="Diego Kaski" name="citation_author"/> <meta content="National Hospital for Neurology and Neurosurgery" name="citation_author_institution"/> <meta content="Otto R Maarsingh" name="citation_author"/> <meta content="Amsterdam Public Health Research Institute" name="citation_author_institution"/> <meta content="Samuel MacKeith" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Jaydip Ray" name="citation_author"/> <meta content="University of Sheffield" name="citation_author_institution"/> <meta content="Vincent A Van Vugt" name="citation_author"/> <meta content="Amsterdam Public Health Research Institute" name="citation_author_institution"/> <meta content="Martin J Burton" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD015187.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015187.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015187.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015187.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [therapeutic use]; *Calcium Channel Blockers [therapeutic use]; Headache; *Migraine Disorders [drug therapy, prevention &amp; control]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015187.pub2&amp;doi=10.1002/14651858.CD015187.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015187\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015187\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","th","ms","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD015187.pub2",title:"Pharmacological interventions for prophylaxis of vestibular migraine",firstPublishedDate:"Apr 12, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015187.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015187.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015187.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015187.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015187.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015187.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015187.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015187.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015187.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015187.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5426 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015187.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/appendices#CD015187-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/supinfo/CD015187StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/supinfo/CD015187StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for prophylaxis of vestibular migraine</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Katie E Webster</a></li> <li class="author custom-tooltip" title="These authors contributed equally"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0005">Afrose Dor</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0006">Kevin Galbraith</a></li> <li class="author custom-tooltip" title="These authors contributed equally"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0007">Luma Haj Kassem</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0008">Natasha A Harrington-Benton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0009">Owen Judd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0010">Diego Kaski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0011">Otto R Maarsingh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0012">Samuel MacKeith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0013">Jaydip Ray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0014">Vincent A Van Vugt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information#CD015187-cr-0015">Martin J Burton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information/en#CD015187-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015187.pub2">https://doi.org/10.1002/14651858.CD015187.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015187-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015187-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015187-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015187-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015187-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015187-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015187-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015187-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015187-abs-0001" lang="en"> <section id="CD015187-sec-0001"> <h3 class="title" id="CD015187-sec-0001">Background</h3> <p>Vestibular migraine is a form of migraine where one of the main features is recurrent attacks of vertigo. These episodes are often associated with other features of migraine, including headache and sensitivity to light or sound. These unpredictable and severe attacks of vertigo can lead to a considerable reduction in quality of life. The condition is estimated to affect just under 1% of the population, although many people remain undiagnosed. A number of pharmacological interventions have been used or proposed to be used as prophylaxis for this condition, to help reduce the frequency of the attacks. These are predominantly based on treatments that are in use for headache migraine, with the belief that the underlying pathophysiology of these conditions is similar.  </p> </section> <section id="CD015187-sec-0002"> <h3 class="title" id="CD015187-sec-0002">Objectives</h3> <p>To assess the benefits and harms of pharmacological treatments used for prophylaxis of vestibular migraine. </p> </section> <section id="CD015187-sec-0003"> <h3 class="title" id="CD015187-sec-0003">Search methods</h3> <p>The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 September 2022. </p> </section> <section id="CD015187-sec-0004"> <h3 class="title" id="CD015187-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs in adults with definite or probable vestibular migraine comparing beta‐blockers, calcium channel blockers, antiepileptics, antidepressants, diuretics, monoclonal antibodies against calcitonin gene‐related peptide (or its receptor), botulinum toxin or hormonal modification with either placebo or no treatment. We excluded studies with a cross‐over design, unless data from the first phase of the study could be identified.  </p> </section> <section id="CD015187-sec-0005"> <h3 class="title" id="CD015187-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome ‐ improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease‐specific health‐related quality of life, 5) improvement in headache, 6) improvement in other migrainous symptoms and 7) other adverse effects. We considered outcomes reported at three time points: &lt; 3 months, 3 to &lt; 6 months, &gt; 6 to 12 months. We used GRADE to assess the certainty of evidence for each outcome.  </p> </section> <section id="CD015187-sec-0006"> <h3 class="title" id="CD015187-sec-0006">Main results</h3> <p>We included three studies with a total of 209 participants. One evaluated beta‐blockers and the other two evaluated calcium channel blockers. We did not identify any evidence for the remaining interventions of interest.  </p> <p><b>Beta‐blockers versus placebo</b> </p> <p>One study (including 130 participants, 61% female) evaluated the use of 95 mg metoprolol once daily for six months, compared to placebo. The proportion of people who reported improvement in vertigo was not assessed in this study. Some data were reported on the frequency of vertigo attacks at six months and the occurrence of serious adverse effects. However, this is a single, small study and for all outcomes the certainty of evidence was low or very low. We are unable to draw meaningful conclusions from the numerical results. </p> <p><b>Calcium channel blockers versus no treatment</b> </p> <p>Two studies, which included a total of 79 participants (72% female), assessed the use of 10 mg flunarizine once daily for three months, compared to no intervention. All of the evidence for this comparison was of very low certainty. Most of our outcomes were only reported by a single study, therefore we were unable to conduct any meta‐analysis. Some data were reported on improvement in vertigo and change in vertigo, but no information was available regarding serious adverse events. We are unable to draw meaningful conclusions from the numerical results, as these data come from single, small studies and the certainty of the evidence was very low.  </p> </section> <section id="CD015187-sec-0007"> <h3 class="title" id="CD015187-sec-0007">Authors' conclusions</h3> <p>There is very limited evidence from placebo‐controlled randomised trials regarding the efficacy and potential harms of pharmacological interventions for prophylaxis of vestibular migraine. We only identified evidence for two of our interventions of interest (beta‐blockers and calcium channel blockers) and all evidence was of low or very low certainty. Further research is necessary to identify whether these treatments are effective at improving symptoms and whether there are any harms associated with their use.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015187-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015187-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015187-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015187-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015187-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015187-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015187-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD015187-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015187-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015187-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015187-abs-0002" lang="en"> <h3>How effective are medicines used to prevent attacks of vestibular migraine</h3> <p><b>Key messages</b> </p> <p>It is not clear whether any medications are effective at preventing attacks of vestibular migraine.  </p> <p>There are very few studies that have assessed the possible benefits and harms of taking medication to prevent attacks. The available studies are small and the results are inconclusive.  </p> <p>Further work is needed in this area to help establish whether there are any treatments that may improve this condition.  </p> <p><b>What is vestibular migraine?</b> </p> <p>Migraine (sometimes known as 'headache migraine') is a common condition that causes recurrent headaches. Vestibular migraine is a related condition where the main symptoms are recurring episodes of severe dizziness or vertigo (a spinning sensation). These episodes are often associated with headache, or other migraine‐like symptoms (such as sensitivity to light or sound, nausea and vomiting). It is a relatively common condition, which affects up to 1 in every 100 people, and can have severe effects on day‐to‐day life.  </p> <p><b>How is vestibular migraine treated?</b> </p> <p>Typical treatment plans include medications to try and stop an attack of vertigo once it has started, or to improve the symptoms. In addition, people may use treatments intended to prevent attacks from starting (prophylactic or preventative treatment). There are no widely recommended treatments to prevent or manage the symptoms of a vestibular migraine attack. People are sometimes advised to take medications used to treat headache migraine. The assumption is that these medicines may also work for vestibular migraine. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out:</p> <p>‐ whether there is evidence that any medications work to prevent attacks of vestibular migraine, or reduce the symptoms when an attack occurs; </p> <p>‐ whether the treatments might cause any harm.</p> <p><b>What did we do?</b> </p> <p>We searched for studies including adults that compared different medications to either no treatment or placebo (dummy) treatment. We used standard methods to assess the certainty of the evidence. We rated our confidence in the evidence, based on factors such as study methods, the number of participants in them and the consistency of findings across studies. </p> <p><b>What did we find?</b> </p> <p>We found three studies, which included a total of 209 people (65% female). These studies looked at two different types of medicines, to assess whether they might help to prevent vestibular migraine attacks, or help to reduce the symptoms when episodes occur.  </p> <p><i>Beta‐blockers</i> </p> <p>The first study looked at the use of a medicine called metoprolol, a tablet taken once daily. Metoprolol is from a group of medications known as beta‐blockers. These are often used to treat high blood pressure, but are also used to try and prevent attacks of headache migraine. It was unclear whether this treatment made any difference to the frequency of vertigo attacks, or whether it was associated with any serious harms.  </p> <p><i>Calcium channel blockers</i> </p> <p>Two smaller studies assessed the use of flunarizine, a tablet taken once a day. This is from the family of medications known as calcium channel blockers. Again, these medicines are commonly used to control high blood pressure, but are also used for headache migraine. It was very unclear whether people felt their symptoms had improved when taking this treatment and whether the frequency of their vertigo attacks changed. The studies did not report on serious harms of the treatment, so we do not know if there were any risks associated with taking the medication.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have very little confidence in the evidence because the three studies conducted were small. There were also some problems with the conduct of the studies, which means that the results may be unreliable. These medications are often used for other conditions, where they are known to be associated with some side effects. However, we did not identify enough information in this review to know whether these side effects are a problem when the treatments are used for vestibular migraine.  </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>This evidence is up‐to‐date to September 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015187-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015187-sec-0130"></div> <h3 class="title" id="CD015187-sec-0131">Implications for practice</h3> <section id="CD015187-sec-0131"> <p>At present there are few placebo‐controlled randomised trials that evaluate pharmacological interventions for the prophylaxis of vestibular migraine. The only evidence we identified evaluated beta‐blockers (specifically, metoprolol) and calcium channel blockers (flunarizine), and we are aware that these medications may not be available in all countries. All of the evidence was of low or very low certainty, therefore we cannot be sure of the efficacy or potential harms of these interventions. People with vestibular migraine (and healthcare professionals who work with them) should be aware of this uncertainty in the evidence to help support decision‐making regarding the possible benefits and risks of treatment. </p> </section> <h3 class="title" id="CD015187-sec-0132">Implications for research</h3> <section id="CD015187-sec-0132"> <p>This review was conducted as part of a suite, which evaluate different interventions for the prophylaxis or acute treatment of vestibular migraine (<a href="./references#CD015187-bbs2-0056" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Non‐pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015321. [DOI: 10.1002/14651858.CD015321]">Webster 2022a</a>; <a href="./references#CD015187-bbs2-0057" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Pharmacological interventions for acute attacks of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015322. [DOI: 10.1002/14651858.CD015322]">Webster 2022b</a>; <a href="./references#CD015187-bbs2-0062" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015187. [DOI: 10.1002/14651858.CD015187]">Webster 2022c</a>). The conclusions below relate to evidence from across the entire suite: </p> <p> <ul id="CD015187-list-0032"> <li> <p>There is a paucity of randomised controlled trials in this field, where active interventions are compared to no treatment or a placebo. Given the subjective nature of symptoms of vestibular migraine, the fluctuating severity of the condition and the lack of a 'gold standard' treatment, we consider that comparison with a placebo arm is vital to allow conclusions to be drawn on the efficacy and harms of different interventions.  </p> </li> <li> <p>Wherever possible, trialists should ensure that participants, study personnel and outcome assessors are appropriately blinded to the intervention, to reduce the risk of performance and detection bias affecting the results of studies.  </p> </li> <li> <p>Small, underpowered studies do little to improve the evidence base for these interventions. We would advocate the conduct of large, adequately powered, multicentre trials to ensure that more robust conclusions can be drawn from the study results. In addition, trialists need to be aware that there is considerable attrition over the course of these studies, and should be prepared to make additional efforts to improve follow‐up.  </p> </li> <li> <p>Future studies should also aim to follow up participants for longer periods of time, to identify whether interventions have lasting effects. </p> </li> <li> <p>There needs to be consensus on the appropriate outcomes to measure in trials that evaluate interventions for vestibular migraine, with input from different stakeholders, especially including those with the condition. As well as agreeing the types of outcomes that are important, the methods with which these are measured should be considered, including the use of validated scales (such as the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM‐PATHI); <a href="./references#CD015187-bbs2-0049" title="SharonJD , KrauterR , KirkL , PasquesiL , AllenIE , FormeisterEJ , et al. Development and validation of VM-PATHI: Vestibular Migraine Patient Assessment Tool and Handicap Inventory. Otology &amp; Neurotology2020;41(4):e494-500.">Sharon 2020</a>), to assess more subjective outcomes. This would be best achieved with the development of a core outcome set, analogous to that developed for use in trials of classical migraine (<a href="./references#CD015187-bbs2-0033" title="HaywoodK , PotterR , FroudR , PearceG , BoxB , MuldoonL , et al. Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open2021;11(11):e043242.">Haywood 2021</a>).  </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015187-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015187-sec-0008"></div> <div class="table" id="CD015187-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with vestibular migraine <br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> beta‐blockers <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in vertigo</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in vertigo frequency</p> <p>Assessed with: number of vertigo attacks per month</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was 3.78 attacks per month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 attacks per month lower<br/>(1.83 lower to 1.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐blockers may result in little or no difference in the number of vertigo attacks at 3 to 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.24 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain as to whether beta‐blockers result in a change in the likelihood of serious adverse events.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/>(37 to 255) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of attrition bias due to substantial dropout over the course of the study. </p> <p><sup>2</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>3</sup>Wide confidence interval, which includes both the potential for considerable harm and potential benefit from the intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015187-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with vestibular migraine <br/><b>Setting: </b> outpatients<br/><b>Intervention:</b> calcium channel blockers <br/><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in vertigo severity</p> <p>Assessed with: "marked improvement" compared to "little/no improvement"</p> <p>Follow‐up: range &lt; 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/>(1.01 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Calcium channel blockers may result in an improvement in the severity of vertigo at less than 3 months follow up, but the evidence is very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>883 per 1000<br/>(615 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in vertigo frequency</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(0.80 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of calcium channel blockers on improvement in vertigo frequency after 6 months of follow‐up.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/>(364 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in vertigo frequency</p> <p>Assessed with: frequency of episodes over a 3‐month period</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in vertigo frequency was 5.5 episodes in 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.3 episodes in 3 months lower<br/>(5.94 lower to 0.66 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blockers may slightly reduce the number of episodes of vertigo after 6 months follow‐up, but the evidence was very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>High risk of selection bias from inadequate allocation concealment (open list of random numbers). High risk of performance and detection bias as participants were aware of their group allocation. </p> <p><sup>2</sup>Participants who had marked improvement were compared to those who had little or no improvement. There is no comparison of those who had some improvement, compared to no improvement. </p> <p><sup>3</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>4</sup>High risk of performance and detection bias as participants were aware of their group allocation. High risk of attrition bias due to differential dropout between the two groups. </p> <p><sup>5</sup>Very wide confidence interval, which includes the possibility of potential harm and potential benefit from the intervention. </p> <p><sup>6</sup>Sample size extremely small (&lt; 15 in each arm). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015187-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015187-sec-0009"></div> <section id="CD015187-sec-0010"> <h3 class="title" id="CD015187-sec-0010">Description of the condition</h3> <p>Vestibular migraine is a form of migraine in which a prominent symptom, often <i>the</i> predominant symptom, is recurrent attacks of vertigo (<a href="./references#CD015187-bbs2-0023" title="DieterichM , BrandtT . Episodic vertigo related to migraine (90 cases): vestibular migraine?Journal of Neurology1999;246(10):883-92. [DOI: 10.1007/s004150050478]">Dieterich 1999</a>; <a href="./references#CD015187-bbs2-0039" title="LempoertT , NeuhauserH . Epidemiology of vertigo, migraine and vestibular migraine. Journal of Neurology2009;256:333-8. [DOI: 10.1007/s00415-009-0149-2]">Lempert 2009</a>). These episodes of vertigo are associated with other migraine features, such as headache or sensitivity to light or sound.  </p> <p>The diagnosis of vestibular migraine is challenging because of the overlap of some symptoms with both other balance disorders (such as Ménière's disease) and with headache migraine. People suffering from headache migraine may experience occasional vestibular symptoms, but this does not amount to a diagnosis of 'vestibular migraine'.  </p> <p>There is now an agreed international classification system, which includes categories for 'definite' and 'probable' vestibular migraine (<a href="./references#CD015187-bbs2-0040" title="LempertT , OlesenJ , FurmanJ , WaterstonJ , SeemungalB , CareyJ , et al. Vestibular migraine: diagnostic criteria. Journal of Vestibular Research2012;22:167-72.">Lempert 2012</a>; described in <a href="./appendices#CD015187-sec-0137">Appendix 1</a>). In brief, a definite diagnosis of vestibular migraine requires at least five episodes of vestibular symptoms (of moderate to severe intensity) lasting between 5 minutes and 72 hours. At least half of the episodes must be associated with migrainous features (such as headache, photophobia, phonophobia or a visual aura) and individuals must also have a history of migraine. A diagnosis of 'probable' vestibular migraine requires similar features, but individuals have either migrainous features or a history of migraines (both are not required). Prior to this internationally agreed classification, the criteria proposed by Neuhauser and colleagues were widely used to identify people with vestibular migraine (<a href="./references#CD015187-bbs2-0042" title="NeuhauserH , LeopoldM , vonBrevernM , ArnoldG , LempertT . The interrelations of migraine, vertigo and migrainous vertigo. Neurology2001;56(4):436-41. [DOI: 10.1212/wnl.56.4.436]">Neuhauser 2001</a>). There is a great deal of similarity between these classification systems, although the Neuhauser criteria do not require a certain number of episodes, or duration of episodes, to make the diagnosis.  </p> <p>Vestibular migraine is the most common cause of recurrent spontaneous vertigo in adults (<a href="./references#CD015187-bbs2-0024" title="DieterichM , ObermannM , CelebisoyN . Vestibular migraine: the most frequent entity of episodic vertigo. Journal of Neurology2016;263:82-9. [DOI: 10.1007/s00415-015-7905-2]">Dieterich 2016</a>). The lifetime prevalence of vestibular migraine has been estimated at just under 1% (<a href="./references#CD015187-bbs2-0043" title="NeuhauserH , RadtkeA , vonBrevernM , FeldmannM , LeziusF , ZieseT , et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology2006;67(6):1028-33.">Neuhauser 2006</a>) and, as such, it is much more common than Ménière's disease. A significant number of cases may still go undiagnosed because of unfamiliarity with the condition or the diagnostic criteria. The disorder may have a slight female preponderance (<a href="./references#CD015187-bbs2-0039" title="LempoertT , NeuhauserH . Epidemiology of vertigo, migraine and vestibular migraine. Journal of Neurology2009;256:333-8. [DOI: 10.1007/s00415-009-0149-2]">Lempert 2009</a>). As with many migraine disorders, a genetic susceptibility has been described and candidate genes have been suggested (<a href="./references#CD015187-bbs2-0026" title="FrejoL , GieglingI , TeggiR , Lopez-EscamezJA , RujescuD . Genetics of vestibular disorders: pathophysiological insights. Journal of Neurology2016;263:45-53. [DOI: 10.1007/s00415-015-7988-9]">Frejo 2016</a>). </p> <p>The pathophysiology of vestibular migraine is still uncertain, but it seems likely to involve similar mechanisms to those of headache migraine. These include activation of the trigeminovascular system (TGVS), which receives nociceptive signals from the large intracranial vessels and the dura (<a href="./references#CD015187-bbs2-0019" title="BernsteinC , BursteinR . Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. Journal of Clinical Neurology2012;8(2):89-99. [DOI: 10.3988/jcn.2012.8.2.89]">Bernstein 2012</a>). Activation of the TGVS results in neuronal stimulation within parts of the brain involved in pain perception and sensory processing (including the thalamus and the periaqueductal grey) and also causes the release of vasoactive neuropeptides, such as calcitonin gene‐related peptide (CGRP). These, in turn, cause dilatation of the meningeal vessels, extravasation of fluid from the vasculature and release of other inflammatory substances in the dura (<a href="./references#CD015187-bbs2-0044" title="PietrobonD , StriessnigJ . Neurobiology of migraine. Nature Reviews Neuroscience2003;4:386-98.">Pietrobon 2003</a>), creating a cycle of nerve stimulation. Cortical hyperexcitability, and subsequent cortical spreading depolarisation, also occurs. This may account for the aura or visual symptoms experienced by many migraineurs (<a href="./references#CD015187-bbs2-0030" title="HadjikhaniN , Sanchez del RioM , WuO , SchwartzD , BakkerD , FischiB , et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences of the United States of America2001;98(8):4687-92. [DOI: 10.1073/pnas.071582498]">Hadjikhani 2001</a>). There may be overlap between headache migraine pathways and those of the vestibular system, accounting for the balance symptoms. For example, the trigeminovascular system receives pain signals from nerves of the dura mater and large intracranial blood vessels, but also from vessels of the inner ear (<a href="./references#CD015187-bbs2-0053" title="VassZ , ShoreSE , NuttallAL , MillerJM . Direct evidence of trigeminal innervation of the cochlear blood vessels. Neuroscience1998;84(11):559-67.">Vass 1998</a>). Abnormal thalamic activation in response to vestibular stimulation has also been identified in patients with vestibular migraine (<a href="./references#CD015187-bbs2-0047" title="RussoA , MarcelliV , EspositoF , CorvinoV , MarcuccioL , GiannoneA , et al. Abnormal thalamic function in patients with vestibular migraine. Neurology2014;82(23):2120-6. [DOI: 10.1212/WNL.0000000000000496]">Russo 2014</a>). CGRP itself is implicated in vestibular migraine, along with headache migraine, and increased CGRP levels have been linked to the development of symptoms in migraine (<a href="./references#CD015187-bbs2-0055" title="VillalónCM , OlesenJ . The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacological Therapy2009;124(3):309-23.">Villalón 2009</a>). Work is ongoing into the relevance of CGRP in vestibular migraine, and whether pharmacological targeting of this molecule and its receptors will affect the condition. </p> <p>The consequences of vestibular migraine for the individual may be considerable. The unpredictable, disabling attacks of vertigo or dizziness can be distressing and debilitating in equal measure. This has a considerable impact on engagement with day‐to‐day activities and overall quality of life.  </p> </section> <section id="CD015187-sec-0011"> <h3 class="title" id="CD015187-sec-0011">Description of the intervention</h3> <p>Current pharmacological treatments for patients with vestibular migraine may be prophylactic, or used to treat an acute attack. Many are based on interventions that have been widely used to treat headache migraine. This review is focused on pharmacological interventions that are taken as prophylaxis, to prevent attacks occurring.  </p> <p>A variety of pharmacological interventions have been used, or proposed, for prophylaxis of vestibular migraine symptoms. These include: </p> <p> <ul id="CD015187-list-0001"> <li> <p>beta‐blockers, for example propranolol;</p> </li> <li> <p>calcium channel blockers, including flunarizine;</p> </li> <li> <p>antiepileptics, such as sodium valproate, topiramate and gabapentin;</p> </li> <li> <p>antidepressants, including amitriptyline;</p> </li> <li> <p>diuretics, such as acetazolamide; </p> </li> <li> <p>monoclonal antibodies against calcitonin gene‐related peptide (CGRP); </p> </li> <li> <p>botulinum toxin;</p> </li> <li> <p>hormonal modification.</p> </li> </ul> </p> </section> <section id="CD015187-sec-0012"> <h3 class="title" id="CD015187-sec-0012">How the intervention might work</h3> <p>There are currently two main targets for headache migraine prophylaxis ‐ either modulation of the pathways that process incoming nociceptive signals, or prevention of neuronal hyperexcitability (<a href="./references#CD015187-bbs2-0045" title="RamadanNM . Current trends in migraine prophylaxis. Headache2007;47(Suppl 1):S52-7.">Ramadan 2007</a>). These principles apply equally to the interventions used for vestibular migraine.  </p> <p>Beta‐blockers have been used for many years in the prophylaxis of headache migraine. They may act by central blockade of β<sub>1</sub> receptors, resulting in a reduction in norepinephrine release and synthesis. There may be additional effects on other neuronal pathways, for example through regulation of neuronal firing in the locus coeruleus and the periaqueductal grey (reviewed in <a href="./references#CD015187-bbs2-0027" title="GallettiF , CupiniLM , CorbelliI , CalabresiP , SarchielliP . Pathological basis of migraine prophylaxis. Progress in Neurobiology2009;89(2):176-92.">Galletti 2009</a>).   </p> <p>The mechanism of action of calcium channel blockers in migraine is not fully understood. They may help to reduce cerebral hypoxia, by preventing vasoconstriction of central vessels, but other mechanisms of action have been suggested ‐ including effects on the nitric oxide pathways and serotonin (reviewed in <a href="./references#CD015187-bbs2-0027" title="GallettiF , CupiniLM , CorbelliI , CalabresiP , SarchielliP . Pathological basis of migraine prophylaxis. Progress in Neurobiology2009;89(2):176-92.">Galletti 2009</a>).  </p> <p>Antiepileptics have multiple sites of action, but many increase GABA‐mediated neurotransmission, and block sodium and calcium channels, consequently reducing neuronal hyperexcitability (<a href="./references#CD015187-bbs2-0054" title="VikelisM , RapoportAM . Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs2010;24:21-33.">Vikelis 2010</a>).  </p> <p>Antidepressants are used for their effect on increasing serotonin levels. Tricyclic antidepressants (such as amitriptyline) and selective serotonin reuptake inhibitors act by preventing neuronal uptake of serotonin (and, for some drugs, norepinephrine), consequently increasing levels of these neurotransmitters (<a href="./references#CD015187-bbs2-0027" title="GallettiF , CupiniLM , CorbelliI , CalabresiP , SarchielliP . Pathological basis of migraine prophylaxis. Progress in Neurobiology2009;89(2):176-92.">Galletti 2009</a>). </p> <p>Diuretics, in particular acetazolamide, have also been used in headache migraine (<a href="./references#CD015187-bbs2-0022" title="De SimoneR , MaranoE , Di StasioE , BonusoS , FiorilloC , BonavitaV . Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache2005;45:385-6.">De Simone 2005</a>), where the mechanism of action is postulated to be due to a direct effect on neuronal ion channels.  </p> <p>CGRP is a neurotransmitter found in numerous locations within the central nervous system and peripheral sensory nerves. Levels of this neurotransmitter have been found to be elevated during headache migraine episodes (<a href="./references#CD015187-bbs2-0028" title="GoadsbyPJ , EdvinssonL , Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology1990;28:183-7.">Goadsby 1990</a>), and to decrease with the use of triptans (<a href="./references#CD015187-bbs2-0029" title="GoadsbyPJ , EdvinssonL . The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology1993;33(1):48-56. [DOI: 10.1002/ana.410330109]">Goadsby 1993</a>). Direct inhibition of the effect of CGRP using monoclonal antibodies may therefore have a potential therapeutic effect on migraine. </p> <p>Botulinum toxin is increasingly used for relief of migraine headache, although the precise mechanism of action is still unclear (reviewed in <a href="./references#CD015187-bbs2-0025" title="DoTP , HvedstrupJ , SchytzHW . Botulinum toxin: a review of the mode of action in migraine. Acta Neurologica Scandinavica2018;137(5):442-51. [DOI: https://doi.org/10.1111/ane.12906]">Do 2018</a> and see also <a href="./references#CD015187-bbs2-0034" title="HerdCP , TomlinsonCL , RickC , ScottonWJ , EdwardsJ , IvesN , et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD011616. [DOI: 10.1002/14651858.CD011616.pub2]">Herd 2018</a>). </p> <p>Headache migraine is well‐recognised to be influenced by hormonal fluctuations, with an increase in migraine frequency typically associated with menstruation and during the peri‐menopause, and an improvement in symptoms during pregnancy and post‐menopause (reviewed in <a href="./references#CD015187-bbs2-0048" title="SaccoS , RicciS , DeganD , CaroleiA . Migraine in women: the role of hormones and their impact on vascular diseases. Journal of Headache and Pain2012;13(3):177-89. [DOI: 10.1007/s10194-012-0424-y]">Sacco 2012</a>). Regulation of hormonal variation may therefore improve symptoms of migraine. However, care must be taken with the choice of treatment due to an increased risk of cardiovascular disease associated with combined oral contraceptives in sufferers of migraine with aura (<a href="./references#CD015187-bbs2-0021" title="ChampalouxSW , TepperNK , MonsourM , CurtisKM , WhitemanMK , MarchbanksPA , et al. Use of combined hormonal contraceptives among women with migraines and risk of ischaemic stroke. American Journal of Obstetrics and Gynaecology2017;216(5):489.e1-e7. [DOI: 10.1016/j.ajog.2016.12.019]">Champaloux 2017</a>). </p> </section> <section id="CD015187-sec-0013"> <h3 class="title" id="CD015187-sec-0013">Why it is important to do this review</h3> <p>Balance disorders can be difficult to diagnose and treat. There are few specific diagnostic tests, a variety of related disorders, and a limited number of interventions that are known to be effective. To determine which topics within this area should be addressed with new or updated systematic reviews, we conducted a scoping and prioritisation process, involving stakeholders (<a href="https://ent.cochrane.org/balance-disorders-ent" target="_blank">https://ent.cochrane.org/balance-disorders-ent</a>). Vestibular migraine was ranked as one of the highest priority topics during this process (along with persistent postural‐perceptual dizziness and Ménière's disease).  </p> <p>The impact of vestibular migraine is considerable, with 40% of sufferers reporting sickness from work, and over 70% reporting the impact of their symptoms on daily activities as either moderate or severe (<a href="./references#CD015187-bbs2-0043" title="NeuhauserH , RadtkeA , vonBrevernM , FeldmannM , LeziusF , ZieseT , et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology2006;67(6):1028-33.">Neuhauser 2006</a>). At present, there are no national or international guidelines to inform the management of this condition, therefore up‐to‐date, reliable evidence syntheses are required to help patients and healthcare professionals determine the benefits and harms of different interventions used for the condition.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015187-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015187-sec-0014"></div> <p>To assess the benefits and harms of pharmacological treatments used for prophylaxis of vestibular migraine. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015187-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015187-sec-0015"></div> <section id="CD015187-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015187-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐randomised trials (where trials were designed as RCTs, but the sequence generation for allocation of treatment used methods such as alternate allocation, birth dates etc).  </p> <p>The number of episodes of vestibular migraine may vary with time ‐ patients sometimes have periods of more active disease, followed by a period of fewer attacks. Therefore cross‐over trials are not an appropriate study design when assessing prophylaxis for this condition. Cross‐over RCTs would only have been included if data could be extracted for the first phase of the study. If cluster‐RCTs were identified then they would have been eligible for inclusion, providing we could appropriately account for the clustering in the data analysis (according to methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>) (<a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). However, we did not identify any cross‐over or cluster‐randomised trials for this review.  </p> </section> <section id="CD015187-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies that recruited participants with a diagnosis of vestibular migraine, according to the International Headache Society (IHS) and Bárány Society criteria (see <a href="./appendices#CD015187-sec-0137">Appendix 1</a>). We also included studies that used other, established criteria, for example <a href="./references#CD015187-bbs2-0042" title="NeuhauserH , LeopoldM , vonBrevernM , ArnoldG , LempertT . The interrelations of migraine, vertigo and migrainous vertigo. Neurology2001;56(4):436-41. [DOI: 10.1212/wnl.56.4.436]">Neuhauser 2001</a>.  </p> <p>We included studies where participants were diagnosed with either 'definite' vestibular migraine or 'probable' vestibular migraine.  </p> <p>Where studies recruited participants with a variety of diagnoses (e.g. vestibular migraine and headache migraine) we planned to include the study if either: </p> <p> <ul id="CD015187-list-0002"> <li> <p>the majority of participants (≥ 90%) had a diagnosis of vestibular migraine; or</p> </li> <li> <p>subgroup data were available that allowed us to identify data specifically from those with vestibular migraine.  </p> </li> </ul> </p> <p>However, we did not identify any studies that included participants with headache migraine.  </p> </section> <section id="CD015187-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions:</p> <p> <ul id="CD015187-list-0003"> <li> <p>beta‐blockers;</p> </li> <li> <p>calcium channel blockers;</p> </li> <li> <p>antiepileptics;</p> </li> <li> <p>antidepressants;</p> </li> <li> <p>diuretics;</p> </li> <li> <p>monoclonal antibodies to CGRP or its receptor;</p> </li> <li> <p>botulinum toxin;</p> </li> <li> <p>hormonal modification.</p> </li> </ul> </p> <p>The main comparisons were planned to be:</p> <p> <ul id="CD015187-list-0004"> <li> <p>beta‐blockers versus placebo/no treatment;</p> </li> <li> <p>calcium channel blockers versus placebo/no treatment;</p> </li> <li> <p>antiepileptics versus placebo/no treatment;</p> </li> <li> <p>antidepressants versus placebo/no treatment;</p> </li> <li> <p>diuretics versus placebo/no treatment;</p> </li> <li> <p>monoclonal antibodies to CGRP or its receptor versus placebo/no treatment;</p> </li> <li> <p>botulinum toxin versus placebo/no treatment;</p> </li> <li> <p>hormonal modification versus placebo/no treatment.</p> </li> </ul> </p> <section id="CD015187-sec-0020"> <h5 class="title">Concurrent treatments</h5> <p>There were no limits on the type of concurrent treatments used, providing these were used equally in each arm of the study. We planned to pool studies that included concurrent treatments with those where participants did not receive concurrent treatment, and to conduct subgroup analysis to determine whether the effect estimates may be different in those receiving additional treatment.  </p> </section> </section> <section id="CD015187-sec-0021"> <h4 class="title">Types of outcome measures</h4> <p>We assessed outcomes at the following time points:</p> <p> <ul id="CD015187-list-0005"> <li> <p>&lt; 3 months;</p> </li> <li> <p>3 to 6 months;</p> </li> <li> <p>&gt; 6 to 12 months.</p> </li> </ul> </p> <p>The exception was for adverse event data, when we used the longest time period of follow‐up.  </p> <p>We searched the COMET database for existing core outcome sets of relevance to vestibular migraine and vertigo, but were unable to find any published core outcome sets. We therefore conducted a survey of individuals with experience of (or an interest in) balance disorders to help identify outcomes that should be prioritised. The results of this survey were used by the review author team to inform the choice of outcome measures in this review. </p> <p>We analysed the following outcomes in the review (but we did not use them as a basis for including or excluding studies). </p> <section id="CD015187-sec-0022"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD015187-list-0006"> <li> <p>Improvement in vertigo</p> <ul id="CD015187-list-0007"> <li> <p>Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of a specified score (as described by the study authors) on a vertigo rating scale. </p> </li> </ul> </li> <li> <p>Change in vertigo</p> <ul id="CD015187-list-0008"> <li> <p>Measured as a continuous outcome, to identify the extent of change in vertigo symptoms.</p> </li> </ul> </li> <li> <p>Serious adverse events</p> <ul id="CD015187-list-0009"> <li> <p>Including any event that caused death, was life‐threatening, required hospitalisation, resulted in disability or permanent damage, or in congenital abnormality. Measured as the number of participants who experienced at least one serious adverse event during the follow‐up period. </p> </li> </ul> </li> </ul> </p> <p>Vertigo symptoms comprise a variety of different features, including frequency of episodes, duration of episodes and severity/intensity of the episodes. Where possible, we included data for the vertigo outcomes that encompassed all of these three aspects (frequency, duration and severity/intensity of symptoms). However, we anticipated that these data may not be available from all studies. If they were unavailable, then we extracted data on the frequency of vertigo episodes as an alternative measure for these outcomes.  </p> </section> <section id="CD015187-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD015187-list-0010"> <li> <p>Disease‐specific health‐related quality of life</p> <ul id="CD015187-list-0011"> <li> <p>Measured with the Dizziness Handicap Inventory (DHI, <a href="./references#CD015187-bbs2-0035" title="JacobsenGP , NewmanCW . The development of the Dizziness Handicap Inventory. Archives of Otolaryngology--Head and Neck Surgery1990;116(4):424-7.">Jacobsen 1990</a>), a validated measurement scale in widespread use. If data from the DHI were unavailable we planned to extract data from alternative validated measurement scales, according to the order of preference described in the list below (based on the validity of the scales for this outcome): </p> <ul id="CD015187-list-0012"> <li> <p>DHI short form (<a href="./references#CD015187-bbs2-0052" title="TesioL , AlpiniD , CesaraniA , PeruccaL . Short form of the Dizziness Handicap Inventory: construction and validation through Rasch analysis. American Journal of Physical Medicine and Rehabilitation1999;78(3):233-41.">Tesio 1999</a>); </p> </li> <li> <p>DHI screening tool (<a href="./references#CD015187-bbs2-0036" title="JacobsenGP , CalderJH . A screening version of the Dizziness Handicap Inventory. American Journal of Otology1998;19(6):804-8.">Jacobsen 1998</a>). </p> </li> </ul> </li> <li> <p>Measured with tools to assess migraine‐related quality of life, such as the Migraine‐Specific Quality of Life Questionnaire (<a href="./references#CD015187-bbs2-0037" title="JhingranP , OsterhausJT , MillerDW , LeeJT , KirchdoerferL . Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache1998;38(4):295-302.">Jhingran 1998</a>). </p> </li> </ul> </li> <li> <p>Improvement in headache </p> <ul id="CD015187-list-0013"> <li> <p>Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of specified score (as described by the study authors) on a headache rating scale. </p> </li> </ul> </li> <li> <p>Improvement in other migrainous symptoms </p> <ul id="CD015187-list-0014"> <li> <p>Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of specified score (as described by the study authors) on a rating scale. </p> </li> <li> <p>Including nausea and vomiting, photophobia and phonophobia, visual aura. </p> </li> </ul> </li> <li> <p>Other adverse effects</p> <ul id="CD015187-list-0015"> <li> <p>Measured as the number of participants who experienced at least one episode of the specified adverse events during the follow‐up period. Including the following specified adverse effects: </p> <ul id="CD015187-list-0016"> <li> <p>gastrointestinal disturbance (e.g. nausea, vomiting, change in bowel habit);</p> </li> <li> <p>sleep disturbance (drowsiness, tiredness or problems sleeping);</p> </li> <li> <p>cardiovascular side effects (e.g. lightheadedness, palpitations);</p> </li> <li> <p>numbness or paraesthesia;</p> </li> <li> <p>dry mouth or blurred vision;</p> </li> <li> <p>skin rash;</p> </li> <li> <p>weight changes.</p> </li> </ul> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD015187-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. The date of the search was 23 September 2022. </p> <section id="CD015187-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched:</p> <p> <ul id="CD015187-list-0017"> <li> <p>the Cochrane ENT Trials Register (searched via the Cochrane Register of Studies to 23 September 2022); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (searched via the Cochrane Register of Studies to 23 September 2022); </p> </li> <li> <p>Ovid MEDLINE(R) Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 23 September 2022); </p> </li> <li> <p>Ovid Embase (1974 to 23 September 2022);</p> </li> <li> <p>Web of Knowledge, Web of Science (1945 to 23 September 2022);</p> </li> <li> <p>ClinicalTrials.gov, <a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> (to 23 September 2022); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="https://trialsearch.who.int/" target="_blank">https://trialsearch.who.int/</a> (to 23 September 2022). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. The strategy has been designed to identify all relevant studies for a suite of reviews on various interventions for vestibular migraine (<a href="./references#CD015187-bbs2-0056" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Non‐pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015321. [DOI: 10.1002/14651858.CD015321]">Webster 2022a</a>; <a href="./references#CD015187-bbs2-0057" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Pharmacological interventions for acute attacks of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015322. [DOI: 10.1002/14651858.CD015322]">Webster 2022b</a>; <a href="./references#CD015187-bbs2-0062" title="WebsterKE , Harrington-BentonNA , JuddO , KaskiD , MaarsinghOR , MacKeithS , et al. Pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015187. [DOI: 10.1002/14651858.CD015187]">Webster 2022c</a>). Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the Technical Supplement to Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> version 6.1) (<a href="./references#CD015187-bbs2-0038" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2020</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD015187-sec-0138">Appendix 2</a>. </p> </section> <section id="CD015187-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors if necessary. In addition, the Information Specialist searched Ovid MEDLINE to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Information Specialist also ran non‐systematic searches of Google Scholar to identify trials not published in mainstream journals. </p> <p>We did not perform a separate search for adverse effects. We considered adverse effects described in included studies only. </p> </section> </section> <section id="CD015187-sec-0027"> <h3 class="title" id="CD015187-sec-0027">Data collection and analysis</h3> <section id="CD015187-sec-0028"> <h4 class="title">Selection of studies</h4> <p>At least two review authors or co‐workers (of AD, KG, LHK, KW, SC) independently screened the remaining titles and abstracts using <a href="https://www.covidence.org" target="_blank">Covidence</a> to identify studies that may be relevant for this review. Any discrepancies were resolved by consensus, or by retrieving the full text of the study for further assessment.  </p> <p>We obtained the full text for any study that may have been relevant and two authors or co‐workers (of AD, KG, LHK, KW) again independently checked this to determine whether it met the inclusion criteria for the review. Any differences were resolved by discussion and consensus, or through recourse to a third author if necessary.  </p> <p>We listed as excluded any studies that were retrieved in full text but subsequently deemed to be inappropriate for the review (according to the inclusion/exclusion criteria), according to the main reason for exclusion.  </p> <p>The unit of interest for the review is the study, therefore multiple papers or reports of a single study have been grouped together under a single reference identification. We recorded the study selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD015187-fig-0001">Figure 1</a>) and the <a href="./references#CD015187-sec-0149" title="">Characteristics of excluded studies</a> table.  </p> <div class="figure" id="CD015187-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow chart of study retrieval and selection." data-id="CD015187-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow chart of study retrieval and selection.</p> </div> </div> </div> <section id="CD015187-sec-0029"> <h5 class="title">Screening eligible studies for trustworthiness</h5> <p>We assessed all studies meeting our inclusion criteria for trustworthiness using a screening tool developed by Cochrane Pregnancy and Childbirth. This tool includes specified criteria to identify studies that are considered sufficiently trustworthy to be included in the review (see <a href="./appendices#CD015187-sec-0139">Appendix 3</a>). If any studies were assessed as being potentially 'high risk', we attempted to contact the study authors to obtain further information or address any concerns. We planned to exclude 'high risk' studies from the main analyses of the review if we were unable to contact the authors, or there was persisting uncertainty about the study, and only include studies with concerns as part of a sensitivity analysis (see <a href="#CD015187-sec-0043">Sensitivity analysis</a>). The process is outlined in <a href="#CD015187-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD015187-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015187-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> </div> <p>However, only one of the three studies included in this review satisfied all criteria for the screening tool (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>). We noted that the study <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> was retrospectively registered, and no protocol was available. In addition, limited baseline characteristics were reported in the article, so we were unable to fully assess the two groups for differences and similarities. Similar concerns were identified with <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>, where no study protocol was identified, and baseline characteristics were reported for the entire cohort, not separately for the two groups.  </p> <p>We attempted to contact study authors to clarify these issues, but received no reply. We had not anticipated this issue when drafting the protocol for our review, but it is likely to be a widespread issue for reviews that incorporate older studies. </p> <p>There are several possible explanations for the studies that had concerns when using the tool. One is that there are issues with the trustworthiness of the studies identified in this review, and the data included may not give reliable estimates of the true effect. Alternatively, the trustworthiness screening tool may be excessively sensitive, and flag studies that are trustworthy, but where information has not been fully reported. We note that this tool (and others used for the same purpose) has not yet been validated for use.  </p> <p>We therefore took the decision to include the studies in the review, despite the potential concerns over trustworthiness. The uncertainty in the results is captured as part of our GRADE rating in the certainty of the evidence, using the domain 'study limitations'.  </p> </section> </section> <section id="CD015187-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (of AD, LHK and KW) independently extracted outcome data from each study using a standardised data collection form. Where a study had more than one publication, we retrieved all publications to ensure complete extraction of data. Any discrepancies in the data extracted by the two authors were checked against the original reports, and differences were resolved through discussion and consensus, with recourse to a third author where necessary. If required, we contacted the study authors for clarification. </p> <p>We included key characteristics of the studies, including the following information:</p> <p> <ul id="CD015187-list-0018"> <li> <p>study design, duration of the study, number of study centres and location, study setting and dates of the study; </p> </li> <li> <p>information on the participants, including the number randomised, those lost to follow‐up or withdrawn, the number analysed, the age of participants, gender, features of the condition (e.g. probable or definite vestibular migraine), diagnostic criteria used, inclusion and exclusion criteria for the individual studies; </p> </li> <li> <p>details of the intervention, comparator, and concomitant treatments or excluded medications;</p> </li> <li> <p>the outcomes specified and reported by the study authors, including the time points;</p> </li> <li> <p>funding for the study and any conflicts of interest for the study authors;</p> </li> <li> <p>information required to assess the risk of bias in the study, and to enable GRADE assessment of the evidence. </p> </li> </ul> </p> <p>Once the extracted data had been checked and any discrepancies resolved, a single author transferred the information to Review Manager 5 (<a href="./references#CD015187-bbs2-0046" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">RevMan 2020</a>).  </p> <p>The primary effect of interest for this review is the effect of treatment assignment (which reflects the outcomes of treatment for people who were assigned to the intervention) rather than a per protocol analysis (the outcomes of treatment only for those who completed the full course of treatment as planned). For the outcomes of interest in this review, we extracted findings from the studies on an available case basis, i.e. all available data from all participants at each time point, based on the treatment to which they were randomised. This was irrespective of adherence, or whether participants had received the intervention as planned. </p> <p>In addition to extracting pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias, we extracted the following summary statistics for each study and outcome: </p> <p> <ul id="CD015187-list-0019"> <li> <p>For continuous data: the mean values, standard deviation and number of patients for each treatment group at the different time points for outcome measurement. Where change‐from‐baseline data were not available, we extracted the values for endpoint data instead. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. mean difference) from the studies. </p> </li> <li> <p>For binary data: we extracted information on the number of participants experiencing an event, and the number of participants assessed at that time point. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. risk ratio) from the studies. </p> </li> <li> <p>For ordinal scale data: if the data appear to be normally distributed, or if the analysis performed by the investigators indicated that parametric tests are appropriate, then we treated the outcome measure as continuous data. Alternatively, if data were available, we converted these to binary data for analysis. </p> </li> <li> <p>For time‐to‐event data: we did not identify any time‐to‐event data for this review. </p> </li> </ul> </p> <p>If necessary, we converted data found in the studies to a format appropriate for meta‐analysis, according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>).  </p> <p>We pre‐specified time points of interest for the outcomes in this review. Where studies reported data at multiple time points, we took the longest available follow‐up point within each of the specific time frames. For example, if a study reported an outcome at 16 weeks and 20 weeks of follow‐up then the 20‐week data was included for the time point three to six months (12 to 24 weeks). </p> </section> <section id="CD015187-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (of AD, LHK, KW) undertook assessment of the risk of bias of the included studies independently, with the following taken into consideration, as guided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015187-bbs2-0031" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Handbook 2011</a>). </p> <p> <ul id="CD015187-list-0020"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane risk of bias tool (<a href="./references#CD015187-bbs2-0031" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Handbook 2011</a>), which involves describing each of these domains as reported in the study and then assigning a judgement about the adequacy of each entry: 'low', 'high' or 'unclear' risk of bias. </p> </section> <section id="CD015187-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the effects of dichotomous outcomes (e.g. serious adverse effects) as risk ratios (RR) with 95% confidence intervals (CIs). We have also expressed the results as absolute numbers based on the pooled results and compared to the assumed risk in the summary of findings tables (<a href="./full#CD015187-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015187-tbl-0002">summary of findings Table 2</a>) and full GRADE profiles (<a href="#CD015187-tbl-0003">Table 1</a>; <a href="#CD015187-tbl-0004">Table 2</a>).  </p> <div class="table" id="CD015187-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">GRADE profile: Beta‐blockers versus placebo for prophylaxis of vestibular migraine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Inconsistency</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Indirectness</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Imprecision</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Publication bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Overall certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study event rates (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With beta‐blockers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with beta‐blockers</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in vertigo frequency (follow‐up: range 3 months to 6 months; assessed with: number of vertigo attacks per month)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was <b>3.78</b> attacks per month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.3 attacks per month lower</b><br/>(1.83 lower to 1.23 higher) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/59 (15.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/62 (9.7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.24 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56 fewer per 1000</b><br/>(from 116 fewer to 102 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Disease‐specific health‐related quality of life (follow‐up: range 3 months to 6 months; assessed with: DHI mean score; scale from: 0 to 4, higher scores = worse quality of life)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the DHI was an increase of <b>0.159</b> points over the follow‐up period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.08 points lower</b><br/>(0.63 lower to 0.47 higher) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in headache frequency (follow‐up: range 3 months to 6 months; assessed with: number of days with headache per month)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean headache frequency was <b>2.4</b> days with headache per month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.1 days with headache per month higher</b><br/>(1.87 lower to 2.08 higher) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>DHI:</b> Dizziness Handicap Inventory; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> <p><sup>a</sup>Risk of attrition bias due to substantial dropout over the course of the study.  </p> <p><sup>b</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>c</sup>Wide confidence interval, which includes both the potential for considerable harm and potential benefit from the intervention.  </p> </div> </div> <div class="table" id="CD015187-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">GRADE profile: Calcium channel blockers versus no intervention for prophylaxis of vestibular migraine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> <br/><b>(studies)</b> <br/><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Inconsistency</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Indirectness</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Imprecision</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Publication bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Overall certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study event rates (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With calcium channel blockers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with calcium channel blockers</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in vertigo severity (follow‐up: range &lt; 3 months; assessed with: "marked improvement" compared to "little/no improvement")</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/23 (60.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/25 (88.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b><br/>(1.01 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>274 more per 1000</b><br/>(from 6 more to 651 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in vertigo frequency (follow‐up: range 3 months to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/11 (45.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/12 (75.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(0.80 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>295 more per 1000</b><br/>(from 91 fewer to 1000 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in vertigo frequency (follow‐up: range 3 months to 6 months; assessed with: frequency of episodes over a 3‐month period)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was <b>5.5</b> episodes in 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.3 episodes in 3 months lower</b><br/>(5.94 lower to 0.66 lower) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in headache (follow‐up: range &lt; 3 months; assessed with: "marked improvement" compared to "little/no improvement")</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/23 (56.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/25 (76.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b><br/>(0.88 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>192 more per 1000</b><br/>(from 68 fewer to 593 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Other adverse effects ‐ drowsiness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37 (13.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 3.85</b><br/>(0.73 to 20.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 more per 1000</b><br/>(from 8 fewer to 351 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Other adverse effects ‐ weight gain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 2.58</b><br/>(0.35 to 18.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 more per 1000</b><br/>(from 19 fewer to 335 more) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> <p><sup>a</sup>High risk of selection bias from inadequate allocation concealment (open list of random numbers). High risk of performance and detection bias as participants were aware of their group allocation. </p> <p><sup>b</sup>Participants who had marked improvement were compared to those who had little or no improvement. There is no comparison of those who had some improvement, compared to no improvement.  </p> <p><sup>c</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>d</sup>High risk of performance and detection bias as participants were aware of their group allocation. High risk of attrition bias due to differential dropout between the two groups.  </p> <p><sup>e</sup>Very wide confidence interval, which includes the possibility of potential harm and potential benefit from the intervention.  </p> <p><sup>f</sup>Sample size extremely small (&lt; 15 in each arm). </p> <p><sup>g</sup>Both studies had a high risk of performance and detection bias. Additional concerns were also present with both studies (attrition bias in <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>, selection bias in <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>). </p> </div> </div> <p>The reported event rate was zero for some outcomes. Therefore, we used the Peto odds ratio (OR) to analyse these data, according to the guidance in <a href="./references#CD015187-bbs2-0058" title="XuC , Furuya-KanamoriL , ZorzelaL , LinL , VohraS . A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. Journal of Clinical Epidemiology2021;135:70-8. [DOI: https://doi.org/10.1016/j.jclinepi.2021.02.012]">Xu 2021</a>, as this should produce less biased estimates of the effect size when events are rare (as described in the <a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>).  </p> <p>For continuous outcomes, we expressed treatment effects as a mean difference (MD) with standard deviation (SD). We did not need to present any data using a standardised mean difference in this review.  </p> </section> <section id="CD015187-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>Vestibular migraine is unlikely to be a stable condition and interventions may not have a temporary effect. If cross‐over trials were identified then we planned to use only the data from the first phase of the study. If cluster‐randomised trials are identified then we will have ensured that analysis methods were used to account for clustering in the data according to the <a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>. However, neither of these study designs were identified in the included studies.  </p> <p>If we had identified studies with three or more arms, we would have ensured these were included to avoid double‐counting of any participants. However, this was not necessary for this review.  </p> </section> <section id="CD015187-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We tried to contact study authors via email whenever the outcome of interest is not reported, if the methods of the study suggested that the outcome had been measured. We planned to do the same if not all data required for meta‐analysis were reported (for example, standard deviations), unless we were able to calculate them from other data reported by the study authors.  </p> </section> <section id="CD015187-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the included studies for potential differences between them in the types of participants recruited, interventions or controls used and the outcomes measured.  </p> <p>We used the I<sup>2</sup> statistic to quantify inconsistency among the studies in each analysis. We also considered the P value from the Chi<sup>2</sup> test. If we had identified substantial heterogeneity, we planned to report this and explore possible causes through pre‐specified subgroup analysis, however this was not necessary.  </p> </section> <section id="CD015187-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias as within‐study outcome reporting bias and between‐study publication bias. </p> <section id="CD015187-sec-0037"> <h5 class="title">Outcome reporting bias (within‐study reporting bias)</h5> <p>We assessed within‐study reporting bias by comparing the outcomes reported in the published report against the study protocol or trial registry, whenever this could be obtained. If the protocol or trial registry entry was not available, we compared the outcomes reported to those listed in the methods section. If results were mentioned but not reported adequately in a way that allows analysis (e.g. the report only mentions whether the results were statistically significant or not), bias in a meta‐analysis is likely to occur. We planned to seek further information from the study authors in this situation. If no further information could be found, we noted this as being a 'high' risk of bias when the risk of bias tool was used. If there was insufficient information to judge the risk of bias we noted this as an 'unclear' risk of bias (<a href="./references#CD015187-bbs2-0031" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Handbook 2011</a>).  </p> </section> <section id="CD015187-sec-0038"> <h5 class="title">Publication bias (between‐study reporting bias)</h5> <p>We planned to assess funnel plots if sufficient studies (more than 10) were available for an outcome. However, we did not identify sufficient studies to enable this. We did not identify any unpublished studies as part of this review.  </p> </section> </section> <section id="CD015187-sec-0039"> <h4 class="title">Data synthesis</h4> <section id="CD015187-sec-0040"> <h5 class="title">Meta‐analysis of numerical data</h5> <p>Where possible and appropriate (if participants, interventions, comparisons and outcomes were sufficiently similar in the studies identified) we conducted a quantitative synthesis of results. We conducted all meta‐analyses using <a href="./references#CD015187-bbs2-0046" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">RevMan 2020</a>. We anticipated that the underlying effect of the intervention may vary between studies, as there are likely to be differences between participants, settings and the interventions used for each study. We therefore planned to use a random‐effects method for meta‐analysis. However, as the only outcomes which we were able to meta‐analyse had few events, this necessitated the use of the fixed effect Peto odds ratio for analysis. We therefore explored whether the use of a random‐effects model substantially altered the effect estimates (see <a href="#CD015187-sec-0043">Sensitivity analysis</a>).  </p> <p>For dichotomous data, we analysed treatment differences as a risk ratio (RR) calculated using the Mantel‐Haenszel methods (or using a Peto odds ratio, as described above). We did not conduct any meta‐analysis for continuous data in this review.  </p> <p>Improvement in vertigo symptoms may be assessed using a variety of methods, which consider different aspects of vertigo. These include: </p> <p> <ul id="CD015187-list-0021"> <li> <p>frequency of vertigo episodes;</p> </li> <li> <p>duration of vertigo episodes;</p> </li> <li> <p>severity/intensity of vertigo episodes;</p> </li> <li> <p>a composite measure of all of these aspects:</p> <ul id="CD015187-list-0022"> <li> <p>for example, assessed with a global score ‐ such as "how troublesome are your vertigo symptoms?", rated on an ordinal scale. </p> </li> </ul> </li> </ul> </p> <p>For the outcomes "improvement in vertigo" and "change in vertigo", we prioritised outcome measures that use a composite score ‐ encompassing aspects of vertigo frequency, duration and severity/intensity. Examples of this include a global rating scale of vertigo impact (rated from 0 to 10, where 0 is defined as no symptoms, and 10 is defined as the most troublesome symptoms) or the vertigo/balance subscale of the Vertigo Symptom Scale (<a href="./references#CD015187-bbs2-0059" title="YardleyL , MassonE , VerschuurC , HaackeN , LuxonL . Symptoms, anxiety and handicap in dizzy patients: development of the vertigo symptom scale. Journal of Psychometric Research1992;36(8):731-41.">Yardley 1992</a>), or Vertigo Symptom Scale Short Form (<a href="./references#CD015187-bbs2-0060" title="YardleyL , BeechS , ZanderL , EvansT , WeinmanJ . A randomized controlled trial of exercise therapy for dizziness and vertigo in primary care. British Journal of General Practice1998;48:1136-40.">Yardley 1998</a>). Where data from composite scores were not available, we included data on the frequency of vertigo episodes as an alternative measure. </p> </section> <section id="CD015187-sec-0041"> <h5 class="title">Synthesis using other methods</h5> <p>If we were unable to pool numerical data in a meta‐analysis for one or more outcomes we planned to provide a synthesis of the results using alternative methods, following the guidance in Chapter 12 of the <a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>. However, this was not necessary, as results were typically provided by a single study.  </p> </section> </section> <section id="CD015187-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If statistical heterogeneity was identified for any comparisons, we planned to assess this considering the following subgroups: </p> <p> <ul id="CD015187-list-0023"> <li> <p>Different types of medication, within a specific class.</p> </li> <li> <p>Use of any concomitant treatment.</p> </li> <li> <p>Diagnosis of vestibular migraine</p> </li> <li> <p>Age of the participants</p> </li> <li> <p>Sex of the participants</p> </li> </ul> </p> <p>However, due to the paucity of data available, and the few meta‐analyses included in this review, we did not carry out any subgroup analysis.  </p> </section> <section id="CD015187-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out a number of sensitivity analyses for the primary outcomes in this review. However, the paucity of data and the lack of meta‐analyses has meant that this was not possible.  </p> <p>If few studies are identified for meta‐analysis, the random‐effects model may provide an inaccurate measure of the between‐studies variance. Therefore, we planned to explore the impact of using a fixed‐effect model using a sensitivity analysis. However, few meta‐analyses were conducted, and these analyses were actually carried out using the Peto OR, a fixed‐effect method, due to zero events in at least one arm of a study. For completeness, we have compared the results to a random‐effects method using the Mantel‐Haenzel OR, but the results are very similar (<a href="#CD015187-tbl-0005">Table 3</a>). </p> <div class="table" id="CD015187-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method of sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a> Drowsiness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 3.85 (95% CI 0.73 to 20.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐effects, Mantel Haenszel OR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.76 (95% CI 0.58 to 24.46)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a> Weight gain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 2.58 (95% CI 0.35 to 18.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐effects, Mantel Haenszel OR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25 (95% CI 0.31 to 16.26)*</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; OR: odds ratio</p> <p>*Note that the primary analysis uses a Peto OR due to the occurrence of zero events in one arm of one study. Therefore, we have assessed the impact of changing to a random‐effects analysis using a Mantel‐Haenszel OR (as the Peto OR cannot use random‐effects). </p> </div> </div> <p>We used the Cochrane Pregnancy and Childbirth Screening Tool to identify any studies with concerns over the data available. We had intended that any studies identified by the tool would be excluded from the main analyses in the review, but that we would explore the impact of including the data from these studies through a sensitivity analysis. However, as noted above, we had some concerns over the use of this tool, and few studies were included in the review, therefore this sensitivity analysis was not conducted.  </p> </section> <section id="CD015187-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two independent authors (KG, KW) used the GRADE approach to rate the overall certainty of evidence using GRADEpro GDT (<a href="https://gradepro.org/" target="_blank">https://gradepro.org/</a>) and the guidance in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015187-bbs2-0032" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Handbook 2021</a>). Disagreements were resolved through discussion and consensus, or with recourse to a third author if necessary. The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD015187-list-0024"> <li> <p>Study limitations (risk of bias):</p> <ul id="CD015187-list-0025"> <li> <p>This was assessed using the rating from the Cochrane risk of bias tool for the study or studies included in the analysis. We rated down either one or two levels, depending on the number of domains that had been rated at high or unclear risk of bias.  </p> </li> </ul> </li> <li> <p>Inconsistency:</p> <ul id="CD015187-list-0026"> <li> <p>This was assessed using the I<sup>2</sup> statistic and the P value for heterogeneity for all meta‐analyses, as well as by visual inspection of the forest plot. For results based on a single study we rated this domain as no serious inconsistency. </p> </li> </ul> </li> <li> <p>Indirectness of evidence:</p> <ul id="CD015187-list-0027"> <li> <p>We took into account whether there were concerns over the population included in the study or studies for each outcome, as well as whether additional treatments were offered that may impact on the efficacy of the intervention under consideration.  </p> </li> </ul> </li> <li> <p>Imprecision:</p> <ul id="CD015187-list-0028"> <li> <p>We took into account the sample size and the width of the confidence interval for each outcome. If the sample size did not meet the optimal information size (i.e. &lt; 400 people for continuous outcomes or &lt; 300 events for dichotomous outcomes), or the confidence interval crossed the small effect threshold we rated down one level. If the sample size did not meet the optimal information size and the confidence interval included both potential harm and potential benefit we rated down twice. We also rated down twice for very tiny studies (e.g. 10 to 15 participants in each arm), regardless of the estimated confidence interval. </p> </li> </ul> </li> <li> <p>Publication bias:</p> <ul id="CD015187-list-0029"> <li> <p>We considered whether there were likely to be unpublished studies that may impact on our confidence in the results obtained.  </p> </li> </ul> </li> </ul> </p> <p>We used a minimally contextualised approach, and rated the certainty in the interventions having an important effect (<a href="./references#CD015187-bbs2-0061" title="ZengL , Brignardello-PetersenR , HultcrantzM , SiemieniukRSC , SantessoN , TraversyG , et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. Journal of Clinical Epidemiology2021;137:163-75.">Zeng 2021</a>). Where possible, we used agreed minimally important differences (MIDs) for continuous outcomes as the threshold for an important difference. Where no MID was identified, we provide an assumed MID based on agreement between the authors. For dichotomous outcomes, we looked at the absolute effects when rating imprecision, but also took into consideration the GRADE default approach (rating down when a RR crosses 1.25 or 0.80). We have justified all decisions to downgrade the certainty of the evidence using footnotes, and added comments to aid the interpretation of the findings, where necessary.  </p> <p>We prepared a separate summary of findings table for the following comparisons:</p> <p> <ul id="CD015187-list-0030"> <li> <p>beta‐blockers versus placebo/no treatment;</p> </li> <li> <p>calcium channel blockers versus placebo/no treatment.</p> </li> </ul> </p> <p>We included all primary outcomes in the summary of findings tables. We prioritised outcomes at the time point three to six months for presentation in the table. However, as some outcomes were only reported at earlier time points, these were also included. We have also included a full GRADE profile for all results and comparisons (<a href="#CD015187-tbl-0003">Table 1</a>; <a href="#CD015187-tbl-0004">Table 2</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015187-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015187-sec-0045"></div> <section id="CD015187-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD015187-sec-0047"> <h4 class="title">Results of the search</h4> <p>The searches in September 2022 retrieved a total of 1186 records. This reduced to 558 after the removal of duplicates. We screened the titles and abstracts of the remaining 558 records. We discarded 534 records and assessed 24 full‐text records. </p> <p>We excluded 14 studies (17 records) with reasons recorded in the review (see <a href="https://unioxfordnexus-my.sharepoint.com/personal/ndos0575_ox_ac_uk/Documents/Reviews/Balance/Meniere's/Searches/EXCLUDED_STUDIES_DESCR" target="_blank">Excluded studies</a> and <a href="./references#CD015187-sec-0149" title="">Characteristics of excluded studies</a>). </p> <p>We identified one ongoing study, which is listed in <a href="./references#CD015187-sec-0150" title="">Characteristics of ongoing studies</a>. </p> <p>We included three completed studies (six records) where results were available.</p> <p>A flow chart of study retrieval and selection is provided in <a href="#CD015187-fig-0001">Figure 1</a>. </p> </section> <section id="CD015187-sec-0048"> <h4 class="title">Included studies</h4> <p>We included three RCTs (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>; <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>; <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>). Details of the individual studies can be found in the <a href="./references#CD015187-sec-0148" title="">Characteristics of included studies</a>. </p> <section id="CD015187-sec-0049"> <h5 class="title">Study design</h5> <p>All of the included studies were described as randomised controlled trials. They all included two arms, comparing an active medication to a placebo, or to no intervention. The duration of treatment ranged from three months (<a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>; <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>) to six months (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>). The largest study was <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>, which recruited a total of 130 participants.  </p> </section> <section id="CD015187-sec-0050"> <h5 class="title">Participants</h5> <p>All three studies recruited adult participants with a diagnosis of vestibular migraine. </p> <section id="CD015187-sec-0051"> <h6 class="title">Diagnosis of vestibular migraine</h6> <p>The study <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> appeared to use the IHS and Bárány Society criteria for the diagnosis of definite vestibular migraine (see <a href="./appendices#CD015187-sec-0137">Appendix 1</a> for details). </p> <p><a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> and <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> used the criteria proposed by <a href="./references#CD015187-bbs2-0042" title="NeuhauserH , LeopoldM , vonBrevernM , ArnoldG , LempertT . The interrelations of migraine, vertigo and migrainous vertigo. Neurology2001;56(4):436-41. [DOI: 10.1212/wnl.56.4.436]">Neuhauser 2001</a>. The study <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> included participants with either 'probable' (38%) or 'definite' (62%) vestibular migraine. It was not clear whether people with both definite and probable vestibular migraine were included in <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>. </p> </section> <section id="CD015187-sec-0052"> <h6 class="title">Features of vestibular migraine</h6> <p>None of the included studies gave details on the duration of the disease in trial participants. The authors of <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> did state that participants in the trial had to experience between 6 and 30 attacks in the three‐month period preceding entry to the study. Similar criteria were applied in <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>, where participants needed to experience at least two attacks per month over the preceding three months. The attack frequency at baseline was not reported in <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>.  </p> </section> </section> <section id="CD015187-sec-0053"> <h5 class="title">Interventions and comparisons</h5> <p>The studies evaluated two of our comparisons of interest. One evaluated metoprolol succinate (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>) and the other two studies evaluated flunarizine (<a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>; <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>).  </p> <section id="CD015187-sec-0054"> <h6 class="title">Comparison 1: Beta‐blockers versus placebo</h6> <p>This comparison was evaluated by <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>. The authors used a dose of 95 mg oral metoprolol succinate once daily, for a period of six months. Short periods of up‐titration (one week of 47.5 mg daily) and tapering (two weeks of 47.5 mg daily) were also included at the start and end of the study. </p> </section> <section id="CD015187-sec-0055"> <h6 class="title">Comparison 2: Calcium channel blockers versus no intervention</h6> <p>Both studies used a dose of 10 mg oral flunarizine once daily, to be taken at night. This was compared to no intervention in the control group.  </p> </section> </section> <section id="CD015187-sec-0056"> <h5 class="title">Outcomes</h5> <section id="CD015187-sec-0057"> <h6 class="title">1. Improvement in vertigo</h6> <p>For this outcome we included dichotomous data, assessed as the proportion of participants whose vertigo had 'improved' or 'not improved'.  </p> <section id="CD015187-sec-0058"> <p><b>1.1. Global score</b></p> <p>The authors of <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> asked participants to rate the improvement in their vertigo symptoms during the study. This was conducted using a five‐point scale (0 to 4, with higher scores representing greater improvement), and analysed by comparing those who had little improvement (score 0 to 2) and those who had marked improvement (score 3 or 4). We considered it likely that this rating would encompass different aspects of vertigo (including the frequency, intensity and the duration of attacks) but this is not explicitly stated in the article. However, interpreting the results from the use of this scale is very challenging. For example, improvements in the frequency of vertigo may be offset by a corresponding increase in vertigo intensity, leading to little change on a global score.  </p> </section> <section id="CD015187-sec-0059"> <p><b>1.2. Frequency</b></p> <p><a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> reported the proportion of participants in whom the frequency of vertigo episodes improved over the three‐month treatment period.  </p> </section> </section> <section id="CD015187-sec-0060"> <h6 class="title">2. Change in vertigo</h6> <p>This outcome included data on the change in vertigo using a continuous numerical scale. </p> <section id="CD015187-sec-0061"> <p><b>2.1. Global score</b></p> <p>No studies reported the change in vertigo symptoms using a global score that considered the frequency, duration and intensity of vertigo attacks.  </p> </section> <section id="CD015187-sec-0062"> <p><b>2.2. Frequency</b></p> <p><a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> reported on the monthly incidence rates of vertigo attacks at the end of the study. <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> reported the frequency of vertigo episodes over the follow‐up period.  </p> </section> </section> <section id="CD015187-sec-0063"> <h6 class="title">3. Serious adverse events</h6> <p>This outcome was assessed and reported by <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>. <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> did not explicitly state that serious adverse events were assessed, although some other (non‐serious) adverse events are reported.  </p> </section> <section id="CD015187-sec-0064"> <h6 class="title">4. Disease‐specific health‐related quality of life</h6> <p>The authors of <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> used the Dizziness Handicap Inventory to assess this outcome.  </p> </section> <section id="CD015187-sec-0065"> <h6 class="title">5. Improvement in headache</h6> <p>This was reported by <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> as the mean number of days with headache per month, rather than as a dichotomous outcome. Improvement in headache was reported by <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> using the same score as used for vertigo. Again, we note the challenges in interpreting results from this global score.  </p> </section> <section id="CD015187-sec-0066"> <h6 class="title">6. Improvement in other migrainous symptoms</h6> <p>This outcome was not assessed by any of the included studies. </p> </section> <section id="CD015187-sec-0067"> <h6 class="title">7. Other adverse effects</h6> <p>Other adverse effects were assessed by <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>, but they did not report specifically on the adverse events of interest in this review (gastrointestinal disturbance, sleep disturbance, cardiovascular side effects, numbness or paraesthesia, dry mouth or blurred vision, skin rash or weight changes). Sleep disturbance and weight gain were both assessed by <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> and <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>.  </p> </section> </section> </section> <section id="CD015187-sec-0068"> <h4 class="title">Excluded studies</h4> <p>After assessing the full text, we excluded 14 studies (linked to 17 records) from this review. The main reason for exclusion for each study is listed below. </p> <p>Three studies were not randomised controlled trials (<a href="./references#CD015187-bbs2-0004" title="ACTRN12616000683437. A test of the balance system in vestibular migraine [Diagnostic value of oVEMPs and cVEMPs in patients with vestibular migraine but without Meniere's disease]. https://anzctr.org.au/ACTRN12616000683437.aspx (first received 25 May 2016). ">ACTRN12616000683437</a>; <a href="./references#CD015187-bbs2-0006" title="ChiCTR1800014766. Multi-center clinical study of patients with vertigo and migraine [Clinical characteristics and evaluation of vestibular eye movements in patients with vestibular migraine ]. http://www.chictr.org.cn/showproj.aspx?proj=24833 (first received 3 February 2018). ">ChiCTR1800014766</a>; <a href="./references#CD015187-bbs2-0007" title="CTRI/2019/09/021185. Flunarizine therapy in reducing vertigo symptoms among patients with vestibular migraine [Prophylactic flunarizine therapy in reducing vestibular symptoms among vestibular migraine patients. An interventional study]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36124 (first received 11 September 2019). ">CTRI/2019/09/021185</a>). </p> <p>Two articles were systematic reviews (<a href="./references#CD015187-bbs2-0005" title="ByunYJ , LevyDA , NguyenSA , BrennanE , RizkHG . Treatment of vestibular migraine: a systematic review and meta-analysis. Laryngoscope2021;131(1):186-94. ">Byun 2021</a>; <a href="./references#CD015187-bbs2-0017" title="WangFZ , WangJQ , CaoYM , XuZX . Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. Regional Anesthesia and Pain Medicine2020;45(5):323-30. ">Wang 2020</a>). We checked the reference lists of these to ensure that any relevant studies had been included in this review.  </p> <p>One study recruited people with headache migraine, not vestibular migraine, therefore we excluded it due to the wrong population (<a href="./references#CD015187-bbs2-0009" title="GordonCR , KuritzkyA , DoweckI , SpitzerO , ShupakA , HeringR . Vestibulo-ocular reflex in migraine patients: the effect of sodium valproate. Headache1993;33(3):129-32. ">Gordon 1993</a>).  </p> <p>Five studies used an incorrect comparator ‐ there was no placebo arm, or group that received no intervention, with which to compare the active intervention(s). These studies included: </p> <p> <ul id="CD015187-list-0031"> <li> <p><a href="./references#CD015187-bbs2-0010" title="LiuF , MaT , CheX , WangQ , YuS . The efficacy of venlafaxine, flunarizine and valproic acid in the prophylaxis of vestibular migraine. Frontiers in Neurology2017;8:524. The efficacy of venlafaxine, flunarizine and valproic acid in the prophylaxis of vestibular migraine. http://www.chictr.org.cn/showproj.aspx?proj=18971 (first received 30 April 2017). ">Liu 2017</a>, which compared flunarizine, valproic acid and venlafaxine; </p> </li> <li> <p><a href="./references#CD015187-bbs2-0008" title="GodeS , CelebisoyN , KirazliT , AkyuzA , BilgenC , KarapolatH , et al. Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache2010;50(1):77-84. ">Gode 2010</a>, which compared high‐dose and low‐dose topiramate; </p> </li> <li> <p><a href="./references#CD015187-bbs2-0015" title="NCT02350985. Comparison of propranolol and venlafaxine in treatment of vestibular migraine [Effectivity of propranolol and venlafaxine in treatment of vestibular migraine: a randomized controlled clinical trial]. https://clinicaltrials.gov/show/NCT02350985 (first received 30 January 2015). SalvizM , YuceT , AcarH , KaratasA , AcikalinRM . Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomised controlled trial. Laryngoscope2016;126(1):169-74. ">Salviz 2015</a>, which compared venlafaxine to propranolol; </p> </li> <li> <p><a href="./references#CD015187-bbs2-0013" title="NCT05472675. Local sensory nerve block in the treatment of vestibular migraine. https://clinicaltrials.gov/ct2/show/NCT05472675 (first received 25 July 2022). ">NCT05472675</a>, which is an ongoing study comparing botulinum toxin and local anaesthetic to beta‐blockers; </p> </li> <li> <p><a href="./references#CD015187-bbs2-0014" title="PACTR201909600414183. Comparison between the efficiency of cinnarizine and topiramate in the treatment of vestibular migraine. http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR201909600414183 (first received 7 January 2019). ">PACTR201909600414183</a>, which compared topiramate to cinnarizine; and </p> </li> <li> <p><a href="./references#CD015187-bbs2-0016" title="NCT01669304. Verapamil vs. sertraline for vestibular migraine &amp; chronic subjective dizziness [Pharmacologic dissection of vestibular migraine and chronic subjective dizziness: a double-blind parallel group trial comparing response to verapamil versus sertraline]. http://clinicaltrials.gov/show/NCT01669304 (first received 21 August 2012). StaabJP , EggersSD , NeffBA , ShepardNT . Vestibular migraine and persistent postural-perceptual dizziness: results of a double blind, parallel group, pharmacologic dissection trial using verapamil and sertraline. Cephalalgia2015;35:65. ">Staab 2015</a>, which compared verapamil to sertraline. </p> </li> </ul> </p> <p>We identified a trial registration for two planned RCTs that did appear to be relevant for this review (one comparing topiramate to placebo, the other comparing 4‐aminopyridine or atenolol to placebo). However, these studies were withdrawn prior to enrolment of any participants, therefore we excluded them (<a href="./references#CD015187-bbs2-0011" title="NCT00732108. Is topiramate effective in treating dizziness in patient's with migraine-associated dizziness [Efficacy of topiramate in patients wih migraine-associated dizziness]. https://clinicaltrials.gov/show/NCT00732108 (first received 11 August 2008). ">NCT00732108</a>; <a href="./references#CD015187-bbs2-0012" title="NCT03578354. 4-aminopyridine, atenolol, or placebo in patients with vestibular migraine [Prospective, randomized, placebo-controlled, phase 2 study of 4-aminopyridine, atenolol, or placebo in the treatment of patients with vestibular migraine]. https://clinicaltrials.gov/show/nct03578354 (first received 31 May 2018). ">NCT03578354</a>). </p> </section> </section> <section id="CD015187-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD015187-fig-0003">Figure 3</a> for the risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies) and <a href="#CD015187-fig-0004">Figure 4</a> for the risk of bias summary (our judgements about each risk of bias item for each included study). All the studies included had some concerns regarding the risk of bias, with at least two domains being rated at high risk of bias.  </p> <div class="figure" id="CD015187-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies)." data-id="CD015187-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies). </p> </div> </div> </div> <div class="figure" id="CD015187-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary (our judgements about each risk of bias item for each included study)." data-id="CD015187-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary (our judgements about each risk of bias item for each included study). </p> </div> </div> </div> <section id="CD015187-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD015187-sec-0071"> <h5 class="title">Random sequence generation</h5> <p>All three studies reported the use of a computerised randomisation schedule, therefore we rated them at low risk for this domain.  </p> </section> <section id="CD015187-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>The use of a web‐based system for randomisation and allocation meant that we rated the study <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> at low risk of bias for allocation concealment.  </p> <p>The trial registration for <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> stated that "an open list of random numbers" was used. We were concerned that this indicated that the randomisation schedule was freely available, and may therefore lead to a high risk of bias from inadequate concealment of allocation.  </p> <p>There was no information available from <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> regarding concealment of allocation, therefore we rated this domain at unclear risk of bias.  </p> </section> </section> <section id="CD015187-sec-0073"> <h4 class="title">Blinding</h4> <section id="CD015187-sec-0074"> <h5 class="title">Blinding of participants and personnel</h5> <p>The authors of <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> used a placebo‐controlled design to ensure that participants were unaware of their group allocation during the study. They also stated that study personnel were not aware of the group allocation for participants. We therefore rated this study at low risk of performance bias.  </p> <p>Two studies were open‐label trials, with no placebo (the comparator group received no intervention), therefore participants and study personnel would have been aware of the group allocations (<a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>; <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>). We rated these studies at high risk of performance bias.  </p> </section> <section id="CD015187-sec-0075"> <h5 class="title">Blinding of outcome assessors</h5> <p>In <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>, outcomes were reported by participants themselves using a daily diary. As participants were blinded to their treatment allocation, we rated this domain at low risk of bias. </p> <p>As the studies by <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> and <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> were open‐label, and outcome assessors were aware of the treatment allocation, we considered the risk of detection bias to be high.  </p> </section> </section> <section id="CD015187-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> reported substantial dropout over the course of the study. This was sufficient to warrant a change in analysis plan from the protocol, to account for the missing data. Although this change may be valid and appropriate, we considered that the extent of missing data had the potential to have a large impact on the study results. Therefore, we rated this study at high risk of attrition bias.  </p> <p><a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> had imbalanced attrition between the two groups, with 22% loss to follow‐up in the control group, compared to 8% in the intervention group. We considered that this would be sufficient to impact on the results of the study, therefore we rated this domain at high risk of bias.   </p> <p>There were few dropouts in <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>, therefore we rated this study at low risk of attrition bias.  </p> </section> <section id="CD015187-sec-0077"> <h4 class="title">Selective reporting</h4> <p>We rated <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> at high risk of selective reporting bias. This was because of the change in analysis plan (as mentioned above, due to missing data) but also because outcomes were intended to be reported at nine months follow‐up (as well as six months) but no data were presented at this time point.  </p> <p>The study <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> was registered with a clinical trial registry, but this was performed retrospectively. We were therefore unable to confirm whether the study had been conducted in accordance with a pre‐specified plan. We rated it at unclear risk of bias from selective reporting. We also rated <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> at unclear risk, as no protocol was identified.  </p> </section> <section id="CD015187-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other concerns over risk of bias for <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> or <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>, therefore we rated this domain at low risk for these studies.  </p> <p>We rated <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> at high risk of other bias. The method used to assess improvement in vertigo was unvalidated, and used an arbitrary cut‐off to distinguish people who experienced 'little improvement' as compared to 'marked improvement'. We were unable to determine the number of people who did not improve at all during the study.  </p> </section> </section> <section id="CD015187-sec-0079"> <h3 class="title" id="CD015187-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD015187-tbl-0001"><b>Summary of findings 1</b> Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</a>; <a href="./full#CD015187-tbl-0002"><b>Summary of findings 2</b> Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</a> </p> <section id="CD015187-sec-0080"> <h4 class="title">1. Beta‐blockers versus placebo </h4> <p>A single study considered this comparison (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>).  </p> <section id="CD015187-sec-0081"> <h5 class="title">1.1. Improvement in vertigo</h5> <p>This outcome was not assessed. </p> </section> <section id="CD015187-sec-0082"> <h5 class="title">1.2. Change in vertigo</h5> <section id="CD015187-sec-0083"> <h6 class="title">1.2.1. Frequency of vertigo</h6> <p>This outcome was assessed as the change in the frequency of vertigo episodes. No data were reported that considered a global score of vertigo severity.  </p> <section id="CD015187-sec-0084"> <p><b>1.2.1.1. &lt; 3 months</b></p> <p>No data were reported at this time point.</p> </section> <section id="CD015187-sec-0085"> <p><b>1.2.1.2. 3 to 6 months</b></p> <p>The mean difference in the frequency of episodes for those receiving metoprolol was a reduction of 0.30 episodes per month (95% confidence interval (CI) ‐1.83 to 1.23; 1 study; 114 participants; low‐certainty evidence; <a href="./references#CD015187-fig-0005" title="">Analysis 1.1</a>). The minimally important difference for a change in frequency of episodes has not been established, however we considered that a change of less than one episode per month may not be considered important by people with vestibular migraine.  </p> </section> <section id="CD015187-sec-0086"> <p><b>1.2.1.3. &gt; 6 to 12 months</b></p> <p>No data were reported at this time point. </p> </section> </section> </section> <section id="CD015187-sec-0087"> <h5 class="title">1.3. Serious adverse events</h5> <p><a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> fully assessed and reported on serious adverse events during the study. The risk ratio (RR) for those receiving metoprolol was 0.63 but the confidence intervals were very wide (95% CI 0.24 to 1.67; 1 study; 121 participants; very low‐certainty evidence; <a href="./references#CD015187-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD015187-sec-0088"> <h5 class="title">1.4. Disease‐specific health‐related quality of life</h5> <p>This was assessed and reported using the Dizziness Handicap Inventory (DHI). Due to the extent of missing data for individual questions on the DHI, the authors analysed this as the mean score per question. Therefore, the data are reported on a scale that ranges from 0 to 4 (higher scores representing worse quality of life), rather than the original DHI scale of 0 to 100. For ease of interpretation we have also provided the data transformed back onto the original scale.  </p> <section id="CD015187-sec-0089"> <h6 class="title">1.4.1. &lt; 3 months</h6> <p>No data were reported at this time point.</p> </section> <section id="CD015187-sec-0090"> <h6 class="title">1.4.2. 3 to 6 months</h6> <p>The mean difference in the DHI mean score at six months was ‐0.08 points (95% CI ‐0.63 to 0.47; 1 study; 91 participants; low‐certainty evidence; <a href="./references#CD015187-fig-0007" title="">Analysis 1.3</a>). If these data are transformed back to the original DHI score (range 0 to 100) then they would indicate a mean difference of ‐2 points (95% CI ‐15.75 to 11.75). This may be a trivial change, as the minimally important difference (MID) for the full DHI score has been suggested to be in the range of 11 to 18 points (<a href="./references#CD015187-bbs2-0035" title="JacobsenGP , NewmanCW . The development of the Dizziness Handicap Inventory. Archives of Otolaryngology--Head and Neck Surgery1990;116(4):424-7.">Jacobsen 1990</a>; <a href="./references#CD015187-bbs2-0051" title="TamberA , WilhelmsenK , Inger StrandL . Measurement properties of the Dizziness Handicap Inventory by cross-sectional and longitudinal designs. Health and Quality of Life Outcomes2009;7:101.">Tamber 2009</a>). </p> </section> <section id="CD015187-sec-0091"> <h6 class="title">1.4.3. &gt; 6 to 12 months</h6> <p>No data were reported at this time point. </p> </section> </section> <section id="CD015187-sec-0092"> <h5 class="title">1.5. Improvement in headache</h5> <p>No dichotomous data were reported that assessed improvement in headache. However, the authors did report the change in headache frequency during the study. Due to the sparsity of other data we have included this as a surrogate measure for this outcome.  </p> <section id="CD015187-sec-0093"> <h6 class="title">1.5.1. &lt; 3 months</h6> <p>No data were reported at this time point.</p> </section> <section id="CD015187-sec-0094"> <h6 class="title">1.5.2. 3 to 6 months</h6> <p>The mean difference in the frequency of headaches per month for those receiving metoprolol was 0.10 (95% CI ‐1.87 to 2.08; 1 study; 91 participants; low‐certainty evidence; <a href="./references#CD015187-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD015187-sec-0095"> <h6 class="title">1.5.3. &gt; 6 to 12 months</h6> <p>No data were reported at this time point. </p> </section> </section> <section id="CD015187-sec-0096"> <h5 class="title">1.6. Improvement in other migrainous symptoms</h5> <p>This outcome was not assessed. </p> </section> <section id="CD015187-sec-0097"> <h5 class="title">1.7. Other adverse effects</h5> <p>Data on adverse effects were collected by the trialists, but a breakdown of the individual adverse effects of interest in this review was not presented.  </p> </section> </section> <section id="CD015187-sec-0098"> <h4 class="title">2. Calcium channel blockers versus no treatment</h4> <p>Two studies addressed this comparison (<a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>; <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>).  </p> <section id="CD015187-sec-0099"> <h5 class="title">2.1. Improvement in vertigo</h5> <section id="CD015187-sec-0100"> <h6 class="title">2.1.2. Global score of vertigo</h6> <p><a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> assessed the improvement of vertigo using a global score. Participants were asked to rate the improvement in their vertigo symptoms using a five‐point scale: 0 = no improvement, 1 = mild improvement, 2 = moderate improvement, 3 = excellent improvement and 4 = completely asymptomatic. This five‐point scale was then separated into "little improvement" (scores 0 to 2) and "marked improvement" (scores 3 or 4). For the purpose of this analysis we were only able to compare those with marked improvement to those with little improvement, although we are aware that this may not accurately estimate the difference between those who experienced "no improvement" and "some improvement".  </p> <section id="CD015187-sec-0101"> <p><b>2.1.2.1. &lt; 3 months</b></p> <p>At 12 weeks, the risk ratio for improvement in those receiving flunarizine was 1.45 (95% CI 1.01 to 2.07; 1 study; 48 participants; very low‐certainty evidence; <a href="./references#CD015187-fig-0009" title="">Analysis 2.1</a>).  </p> </section> <section id="CD015187-sec-0102"> <p><b>2.1.2.2. 3 to 6 months</b></p> <p>No data were reported at this time point. </p> </section> <section id="CD015187-sec-0103"> <p><b>2.1.2.3. 6 to 12 months</b></p> <p>No data were reported at this time point. </p> </section> </section> <section id="CD015187-sec-0104"> <h6 class="title">2.1.3. Frequency of vertigo</h6> <p>The authors of <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> assessed the number of participants in whom the frequency of vertigo had improved over the course of the study. It was not clear how 'improvement' was defined ‐ we assume that this means a reduction in the number of vertigo episodes of at least one over the course of the study.  </p> <section id="CD015187-sec-0105"> <p><b>2.1.3.1. &lt; 3 months</b></p> <p>No data were reported at this time point.</p> </section> <section id="CD015187-sec-0106"> <p><b>2.1.3.2. 3 to 6 months</b></p> <p>At three months, the number of participants in whom the frequency of vertigo had improved was higher in the flunarizine group, with a risk ratio of 1.65, although the confidence interval was wide (95% 0.80 to 3.41; 1 study; 23 participants; very low‐certainty evidence; <a href="./references#CD015187-fig-0010" title="">Analysis 2.2</a>).  </p> </section> <section id="CD015187-sec-0107"> <p><b>2.1.3.3. 6 to 12 months</b></p> <p>No data were reported at this time point.  </p> </section> </section> </section> <section id="CD015187-sec-0108"> <h5 class="title">2.2. Change in vertigo</h5> <section id="CD015187-sec-0109"> <h6 class="title">2.2.1. Global score of vertigo</h6> <p>No data were reported that considered a global score of vertigo severity. </p> </section> <section id="CD015187-sec-0110"> <h6 class="title">2.2.2. Frequency of vertigo</h6> <p>This outcome was assessed as the change in the frequency of vertigo episodes during a three‐month period.  </p> <section id="CD015187-sec-0111"> <p><b>2.2.2.1. &lt; 3 months</b></p> <p>No data were reported at this time point.</p> </section> <section id="CD015187-sec-0112"> <p><b>2.2.2.2. 3 to 6 months</b></p> <p>The mean difference in the frequency of episodes for those receiving flunarizine was a reduction of 3.30 episodes over a three‐month period (95% CI ‐5.94 to ‐0.66; 1 study; 23 participants; very low‐certainty evidence; <a href="./references#CD015187-fig-0011" title="">Analysis 2.3</a>). This would equate to a reduction of about one episode per month. The minimally important difference for a change in frequency of episodes has not been established, however we considered that a change of one episode per month may be considered important by people with vestibular migraine.  </p> </section> <section id="CD015187-sec-0113"> <p><b>2.2.2.3. &gt; 6 to 12 months</b></p> <p>No data were reported at this time point. </p> </section> </section> </section> <section id="CD015187-sec-0114"> <h5 class="title">2.3 Serious adverse events</h5> <p>It is not clear whether data on serious adverse events were specifically collected as part of these studies. The authors do report a small number of other adverse effects, which do not appear to be serious from the description (see below). We therefore presumed that there were no serious adverse events in either group, but this is not explicit.  </p> </section> <section id="CD015187-sec-0115"> <h5 class="title">2.4. Disease‐specific health‐related quality of life</h5> <p>This outcome was not assessed. </p> </section> <section id="CD015187-sec-0116"> <h5 class="title">2.5. Improvement in headache</h5> <p><a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> assessed improvement in headache using the same score as for vertigo. Again, participants were grouped into those who had "little improvement" and those who had "marked improvement".  </p> <section id="CD015187-sec-0117"> <h6 class="title">2.5.1. &lt; 3 months</h6> <p>At 12 weeks, the risk ratio for improvement in headache for those receiving flunarizine was 1.34 (95% CI 0.88 to 2.05; 1 study; 48 participants; very low‐certainty evidence; <a href="./references#CD015187-fig-0012" title="">Analysis 2.4</a>).  </p> </section> <section id="CD015187-sec-0118"> <h6 class="title">2.5.2. 3 to 6 months</h6> <p>No data were reported at this time point. </p> </section> <section id="CD015187-sec-0119"> <h6 class="title">2.5.3. 6 to 12 months</h6> <p>No data were reported at this time point. </p> </section> </section> <section id="CD015187-sec-0120"> <h5 class="title">2.6. Improvement in other migrainous symptoms</h5> <p>This outcome was not assessed. </p> </section> <section id="CD015187-sec-0121"> <h5 class="title">2.7. Other adverse effects</h5> <p>The authors of both studies reported on some of our pre‐specified adverse effects of interest. As noted in <a href="#CD015187-sec-0039">Data synthesis</a>, we used the Peto odds ratio for these analyses, due to the low event rates. The Peto odds ratio for drowsiness in those receiving flunarizine was 3.85 (95% CI 0.73 to 20.26; 2 studies; 71 participants; I<sup>2</sup> = 0%; very low‐certainty evidence; <a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a>). The Peto odds ratio for weight gain in those receiving flunarizine was 2.58 (95% CI 0.35 to 18.94; 2 studies; 71 participants; I<sup>2</sup> = 0%; very low‐certainty evidence; <a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a>).  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015187-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015187-sec-0122"></div> <section id="CD015187-sec-0123"> <h3 class="title" id="CD015187-sec-0123">Summary of main results</h3> <p>We identified only three studies for inclusion in this review. They evaluated two of our proposed interventions of interest: beta‐blockers and calcium channel blockers for prophylaxis of vestibular migraine.  </p> <section id="CD015187-sec-0124"> <h4 class="title">Beta‐blockers versus placebo</h4> <p>One study assessed this comparison ‐ participants were randomised to receive either 95 mg metoprolol once daily or a placebo. Metoprolol may make little or no difference to the frequency of vertigo episodes, disease‐specific quality of life and the frequency of headaches at between three and six months of follow‐up. The evidence regarding the occurrence of serious adverse effects was very uncertain. The other outcomes we prioritised in this review were not reported by the authors of this study (improvement in vertigo, improvement in other migrainous symptoms and other adverse effects).  </p> </section> <section id="CD015187-sec-0125"> <h4 class="title">Calcium channel blockers versus no intervention</h4> <p>Two studies evaluated this comparison, both using a dose of 10 mg flunarizine daily. All of the evidence for this comparison was of very low certainty. Participants receiving flunarizine may be more likely to report improvement in vertigo (when assessed using a global score of vertigo symptoms), but the evidence is very uncertain. The frequency of vertigo episodes may also be slightly reduced for those who receive flunarizine but, again, the certainty of the evidence was very low. The evidence was very uncertain about the effect of flunarizine on improvement in vertigo (when assessed as a dichotomous outcome, rather than using a continuous scale) and headache. Flunarizine may result in an increase in the side effects of weight gain and drowsiness, but the confidence intervals were very wide and the evidence is very uncertain. We did not identify any data on serious adverse events, disease‐specific quality of life or other migrainous symptoms.  </p> </section> </section> <section id="CD015187-sec-0126"> <h3 class="title" id="CD015187-sec-0126">Overall completeness and applicability of evidence</h3> <p>We only identified three studies that were eligible for inclusion in this review, and they evaluated just two of the interventions of interest. No placebo‐controlled randomised controlled trials (RCTs) were identified that considered other interventions which have been used, or proposed for use, in people with vestibular migraine. This includes antiepileptics, antidepressants, diuretics, monoclonal antibodies to calcitonin gene‐related peptide (CGRP) or its receptor, botulinum toxin and hormonal treatment. </p> <p>Two of the studies included in this review enrolled participants who were experiencing at least two attacks of vestibular migraine per month. Therefore, most of the evidence here may relate to individuals who have relatively frequent attacks, and may not apply to those who experience less frequent episodes. We note that vestibular and headache symptoms may vary considerably between different individuals, and may also fluctuate over time. In addition, follow‐up for all included studies was for between three and six months, so we do not have any evidence regarding longer‐term follow‐up. The limited data available also meant that we were unable to conduct any subgroup analysis, so the relative efficacy and harms of these interventions in different subgroups of people with vestibular migraine is uncertain.  </p> <p>We did identify some evidence for most of our pre‐specified outcomes of interest in this review. However, no evidence was identified regarding associated migrainous symptoms (other than headache or vertigo), including photophobia, phonophobia, nausea and vomiting and visual aura. We also found only very limited information on potential adverse effects of these interventions.  </p> <p>We noted that the description of outcome measures was sometimes inadequate in the studies ‐ it was difficult to identify how outcomes were assessed and whether this was appropriate. For example, the study <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> reported on 'improvement' in vertigo frequency, but did not provide a clear description of how vertigo was judged to have improved. The study <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> considered improvement in vertigo using an ordinal scoring system, which did not appear to have been validated for use. In addition, a fairly arbitrary cut‐off was used to separate those who had 'marked improvement' from those who had 'little improvement'. The use of different tools for measuring symptoms of vestibular migraine makes it difficult to pool results across studies. In addition, many of these tools do not appear to have been subject to rigorous assessment and validation for measuring symptoms of vestibular migraine. Therefore it is difficult to know whether they accurately estimate the change in symptoms with treatment.  </p> </section> <section id="CD015187-sec-0127"> <h3 class="title" id="CD015187-sec-0127">Quality of the evidence</h3> <p>We assessed all the evidence in this review as either low‐ or very low‐certainty, using the GRADE approach. This shows that our confidence in the estimates of effect is low, and that additional data from future studies are likely to change these estimates.  </p> <p>Imprecision in the effect estimates was a major contributor to the low certainty of the evidence. The studies included in this review were all relatively small (ranging from 27 to 130 participants), and often the confidence intervals for any effect were wide, sometimes ranging from the possibility of a beneficial effect to the possibility of a harmful effect from the intervention. </p> <p>We had concerns over the risk of bias for the studies included in the review. The studies <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> and <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> were open‐label, where participants and study personnel were aware of the treatment allocation, leading to a high risk of performance bias and detection bias. There were also additional concerns in other domains for both of these studies. We considered the largest study at low risk of bias for most domains (<a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a>). However, due to considerable dropout during the trial we assessed it at high risk of attrition bias. However, we also had concerns over the possibility of selective reporting bias, as outcomes were not reported at the intended final follow‐up point. </p> <p>As described above, we also had some concerns over the methods used to assess some outcomes. The certainty of the evidence was reduced for indirectness if the outcome had been assessed using an unvalidated scale, or the outcome reported did not fully align with our pre‐specified outcomes of interest. This was the case for improvement in vertigo and headache as reported by <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>, where they compared participants with 'marked improvement' to those with 'little or no improvement', when we were intending to assess those with 'any improvement' compared to none.  </p> </section> <section id="CD015187-sec-0128"> <h3 class="title" id="CD015187-sec-0128">Potential biases in the review process</h3> <p>A number of RCTs were excluded from this review as the comparator was incorrect ‐ an intervention was not compared to placebo or no treatment, but was instead compared to another (potentially) active intervention. This may be regarded as a source of bias in the review, although it is in accordance with our protocol. As the efficacy for different interventions in vestibular migraine is unknown, and there is no 'gold standard' treatment, we strongly felt that interventions must be compared to no treatment (or placebo treatment) in order to accurately estimate their effects. However, future reviews may consider addressing this problem with the use of network meta‐analysis.  </p> <p>As noted in <a href="#CD015187-sec-0028">Selection of studies</a>, we intended to use the Trustworthiness Screening Tool to select studies that would be included in the main analyses in this review. We had concerns regarding the methods used in two of the included studies when using this tool, but we were unable to establish contact with the authors to provide clarification. However, due to the paucity of data, and some concerns over the sensitivity of the tool, we decided to include all three studies in the main analyses of this review. Nonetheless, the evidence from these two studies is already rated as very low‐certainty, therefore the conclusions of this review are unlikely to be different, even if these studies were known to have problems in their conduct or reporting.  </p> </section> <section id="CD015187-sec-0129"> <h3 class="title" id="CD015187-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>A previous Cochrane Review was prepared on this topic in 2016 but no studies were included (<a href="./references#CD015187-bbs2-0041" title="Maldonado FernándezM , BirdiJS , IrvingGJ , MurdinL , KivekäsI , StruppM . Pharmacological agents for the prevention of vestibular migraine. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010600. [DOI: 10.1002/14651858.CD010600.pub2]">Maldonado Fernández 2015</a>). At the time of publication for the previous review, the studies <a href="./references#CD015187-bbs2-0001" title="BayerO , AdrionC , Al TawilA , MansmannU , Strupp M and PROVEMIG investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials2019;20:813. [DOI: 10.1186/s13063-019-3903-5]DRKS00005040. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00005040 (first received 22 August 2013). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol [Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial]. https://www.isrctn.com/ISRCTN72824329 (first received 19 August 2009). ISRCTN72824329. Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN72824329 (first received 19 August 2009). ">Bayer 2019</a> and <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a> had not been completed. The study <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a> was also excluded from the original Cochrane Review, as the study used the <a href="./references#CD015187-bbs2-0042" title="NeuhauserH , LeopoldM , vonBrevernM , ArnoldG , LempertT . The interrelations of migraine, vertigo and migrainous vertigo. Neurology2001;56(4):436-41. [DOI: 10.1212/wnl.56.4.436]">Neuhauser 2001</a> criteria for diagnosis of vestibular migraine, rather than the International Headache Society (IHS) criteria. We considered that these two sets of diagnostic criteria were sufficiently similar that studies using either should be included in the review.  </p> <p>We identified a recent systematic review that assessed the use of a number of different pharmacological interventions for vestibular migraine (antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, beta‐blockers, serotonin and norepinephrine reuptake inhibitors), as well as vestibular rehabilitation (<a href="./references#CD015187-bbs2-0005" title="ByunYJ , LevyDA , NguyenSA , BrennanE , RizkHG . Treatment of vestibular migraine: a systematic review and meta-analysis. Laryngoscope2021;131(1):186-94. ">Byun 2021</a>). This review differs from our own in two important ways. Firstly, the authors included non‐randomised studies as well as RCTs. In addition, meta‐analyses were conducted using data collected before and after treatment for all studies. Therefore, the comparison between randomised groups was not maintained (even when analysing data from RCTs) and the studies were analysed as if they were non‐comparative cohort studies. In this review, many of these treatments appeared to show efficacy for improvement in the frequency of vestibular migraine attacks, reduction (improvement) in Dizziness Handicap Inventory (DHI) scores and overall improvement in symptoms. However, there was no comparison with an appropriate control group for any of these analyses, therefore it is not possible to comment on how much of this improvement was related to the intervention itself. Given the fluctuation in symptoms of vestibular migraine we considered that these data may not accurately reflect the efficacy of these treatments. Nonetheless, <a href="./references#CD015187-bbs2-0005" title="ByunYJ , LevyDA , NguyenSA , BrennanE , RizkHG . Treatment of vestibular migraine: a systematic review and meta-analysis. Laryngoscope2021;131(1):186-94. ">Byun 2021</a> and colleagues do draw some similar conclusions to our own review, including the need for a longer duration of follow‐up, and the overall paucity of evidence from randomised controlled trials.  </p> <p>Another recent systematic review evaluated the use of pharmacological (and non‐pharmacological) interventions for both the prophylaxis and acute treatment of vestibular migraine (<a href="./references#CD015187-bbs2-0050" title="SmythD , BrittonZ , MurdinL , ArshadQ , KaskiD . Vestibular migraine treatment: a comprehensive practical review. Brain2022;145(11):3741-54. [DOI: https://doi.org/10.1093/brain/awac264]">Smyth 2022</a>). Again, the authors of this review included both randomised and non‐randomised studies, therefore the results are not directly comparable with our own review. However, again the conclusions are similar ‐ that the overall evidence base for the treatment of vestibular migraine is of low certainty, and that well‐designed clinical trials are required in this area.   </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015187-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow chart of study retrieval and selection." data-id="CD015187-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow chart of study retrieval and selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-FIG-02" target="_blank"><b></b></a></p> </div><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015187-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies)." data-id="CD015187-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary (our judgements about each risk of bias item for each included study)." data-id="CD015187-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary (our judgements about each risk of bias item for each included study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo, Outcome 1: Change in vertigo frequency" data-id="CD015187-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo, Outcome 1: Change in vertigo frequency</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo, Outcome 2: Serious adverse events" data-id="CD015187-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo, Outcome 2: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo, Outcome 3: Disease‐specific health‐related quality of life" data-id="CD015187-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo, Outcome 3: Disease‐specific health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo, Outcome 4: Change in headache frequency" data-id="CD015187-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo, Outcome 4: Change in headache frequency</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Calcium channel blockers versus no intervention, Outcome 1: Improvement in vertigo severity" data-id="CD015187-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Calcium channel blockers versus no intervention, Outcome 1: Improvement in vertigo severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Calcium channel blockers versus no intervention, Outcome 2: Improvement in vertigo frequency" data-id="CD015187-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Calcium channel blockers versus no intervention, Outcome 2: Improvement in vertigo frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Calcium channel blockers versus no intervention, Outcome 3: Change in vertigo frequency" data-id="CD015187-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Calcium channel blockers versus no intervention, Outcome 3: Change in vertigo frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Calcium channel blockers versus no intervention, Outcome 4: Improvement in headache " data-id="CD015187-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Calcium channel blockers versus no intervention, Outcome 4: Improvement in headache  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015187-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/urn:x-wiley:14651858:media:CD015187:CD015187-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Calcium channel blockers versus no intervention, Outcome 5: Other adverse effects" data-id="CD015187-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_t/tCD015187-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Calcium channel blockers versus no intervention, Outcome 5: Other adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/media/CDSR/CD015187/image_n/nCD015187-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015187-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with vestibular migraine <br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> beta‐blockers <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in vertigo</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in vertigo frequency</p> <p>Assessed with: number of vertigo attacks per month</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was 3.78 attacks per month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 attacks per month lower<br/>(1.83 lower to 1.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐blockers may result in little or no difference in the number of vertigo attacks at 3 to 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.24 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain as to whether beta‐blockers result in a change in the likelihood of serious adverse events.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/>(37 to 255) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of attrition bias due to substantial dropout over the course of the study. </p> <p><sup>2</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>3</sup>Wide confidence interval, which includes both the potential for considerable harm and potential benefit from the intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo for prophylaxis of vestibular migraine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015187-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with vestibular migraine <br/><b>Setting: </b> outpatients<br/><b>Intervention:</b> calcium channel blockers <br/><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with calcium channel blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in vertigo severity</p> <p>Assessed with: "marked improvement" compared to "little/no improvement"</p> <p>Follow‐up: range &lt; 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/>(1.01 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Calcium channel blockers may result in an improvement in the severity of vertigo at less than 3 months follow up, but the evidence is very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>883 per 1000<br/>(615 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in vertigo frequency</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(0.80 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of calcium channel blockers on improvement in vertigo frequency after 6 months of follow‐up.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/>(364 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in vertigo frequency</p> <p>Assessed with: frequency of episodes over a 3‐month period</p> <p>Follow‐up: range 3 months to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in vertigo frequency was 5.5 episodes in 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.3 episodes in 3 months lower<br/>(5.94 lower to 0.66 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>3,4,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blockers may slightly reduce the number of episodes of vertigo after 6 months follow‐up, but the evidence was very uncertain.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>High risk of selection bias from inadequate allocation concealment (open list of random numbers). High risk of performance and detection bias as participants were aware of their group allocation. </p> <p><sup>2</sup>Participants who had marked improvement were compared to those who had little or no improvement. There is no comparison of those who had some improvement, compared to no improvement. </p> <p><sup>3</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>4</sup>High risk of performance and detection bias as participants were aware of their group allocation. High risk of attrition bias due to differential dropout between the two groups. </p> <p><sup>5</sup>Very wide confidence interval, which includes the possibility of potential harm and potential benefit from the intervention. </p> <p><sup>6</sup>Sample size extremely small (&lt; 15 in each arm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015187-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">GRADE profile: Beta‐blockers versus placebo for prophylaxis of vestibular migraine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Inconsistency</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Indirectness</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Imprecision</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Publication bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Overall certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study event rates (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With beta‐blockers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with beta‐blockers</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in vertigo frequency (follow‐up: range 3 months to 6 months; assessed with: number of vertigo attacks per month)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was <b>3.78</b> attacks per month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.3 attacks per month lower</b><br/>(1.83 lower to 1.23 higher) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/59 (15.3%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/62 (9.7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.24 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56 fewer per 1000</b><br/>(from 116 fewer to 102 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Disease‐specific health‐related quality of life (follow‐up: range 3 months to 6 months; assessed with: DHI mean score; scale from: 0 to 4, higher scores = worse quality of life)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in the DHI was an increase of <b>0.159</b> points over the follow‐up period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.08 points lower</b><br/>(0.63 lower to 0.47 higher) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in headache frequency (follow‐up: range 3 months to 6 months; assessed with: number of days with headache per month)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean headache frequency was <b>2.4</b> days with headache per month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.1 days with headache per month higher</b><br/>(1.87 lower to 2.08 higher) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>DHI:</b> Dizziness Handicap Inventory; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> <p><sup>a</sup>Risk of attrition bias due to substantial dropout over the course of the study.  </p> <p><sup>b</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>c</sup>Wide confidence interval, which includes both the potential for considerable harm and potential benefit from the intervention.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">GRADE profile: Beta‐blockers versus placebo for prophylaxis of vestibular migraine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015187-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">GRADE profile: Calcium channel blockers versus no intervention for prophylaxis of vestibular migraine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> <br/><b>(studies)</b> <br/><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Inconsistency</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Indirectness</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Imprecision</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Publication bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Overall certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study event rates (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With calcium channel blockers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with calcium channel blockers</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in vertigo severity (follow‐up: range &lt; 3 months; assessed with: "marked improvement" compared to "little/no improvement")</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/23 (60.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/25 (88.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b><br/>(1.01 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>274 more per 1000</b><br/>(from 6 more to 651 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in vertigo frequency (follow‐up: range 3 months to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/11 (45.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/12 (75.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(0.80 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>295 more per 1000</b><br/>(from 91 fewer to 1000 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Change in vertigo frequency (follow‐up: range 3 months to 6 months; assessed with: frequency of episodes over a 3‐month period)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency was <b>5.5</b> episodes in 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.3 episodes in 3 months lower</b><br/>(5.94 lower to 0.66 lower) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Improvement in headache (follow‐up: range &lt; 3 months; assessed with: "marked improvement" compared to "little/no improvement")</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/23 (56.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/25 (76.0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b><br/>(0.88 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>192 more per 1000</b><br/>(from 68 fewer to 593 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Other adverse effects ‐ drowsiness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37 (13.5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 3.85</b><br/>(0.73 to 20.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 more per 1000</b><br/>(from 8 fewer to 351 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign="top"> <p><b>Other adverse effects ‐ weight gain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very serious<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/37 (8.1%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 2.58</b><br/>(0.35 to 18.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 more per 1000</b><br/>(from 19 fewer to 335 more) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> <p><sup>a</sup>High risk of selection bias from inadequate allocation concealment (open list of random numbers). High risk of performance and detection bias as participants were aware of their group allocation. </p> <p><sup>b</sup>Participants who had marked improvement were compared to those who had little or no improvement. There is no comparison of those who had some improvement, compared to no improvement.  </p> <p><sup>c</sup>Optimal information size was not reached (taken as &lt; 400 participants for continuous outcomes or &lt; 300 events for dichotomous outcomes, as a rule of thumb). </p> <p><sup>d</sup>High risk of performance and detection bias as participants were aware of their group allocation. High risk of attrition bias due to differential dropout between the two groups.  </p> <p><sup>e</sup>Very wide confidence interval, which includes the possibility of potential harm and potential benefit from the intervention.  </p> <p><sup>f</sup>Sample size extremely small (&lt; 15 in each arm). </p> <p><sup>g</sup>Both studies had a high risk of performance and detection bias. Additional concerns were also present with both studies (attrition bias in <a href="./references#CD015187-bbs2-0003" title="YuanQ , LiuDL , YuLS , ZhangQF . Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2016;30(10):805-10. ">Yuan 2016</a>, selection bias in <a href="./references#CD015187-bbs2-0002" title="CTRI/2012/07/002779. Frequency of migraine associated vertigo in patients visiting the audiovestibular clinic in a tertiary care hospital and response to specific treatment for migraine. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=4796&amp;EncHid=&amp;modid=&amp;compid=%27,%274796det%27 (first received 9 July 2012). LepchaA , AmalananthanS , AugustineAM , TyagiAK , BalrajA . Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. European Archives of Oto-Rhino-Laryngology2014;271(11):2931-6. ">Lepcha 2014</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">GRADE profile: Calcium channel blockers versus no intervention for prophylaxis of vestibular migraine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015187-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method of sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a> Drowsiness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 3.85 (95% CI 0.73 to 20.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐effects, Mantel Haenszel OR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.76 (95% CI 0.58 to 24.46)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015187-fig-0013" title="">Analysis 2.5</a> Weight gain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 2.58 (95% CI 0.35 to 18.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐effects, Mantel Haenszel OR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25 (95% CI 0.31 to 16.26)*</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; OR: odds ratio</p> <p>*Note that the primary analysis uses a Peto OR due to the occurrence of zero events in one arm of one study. Therefore, we have assessed the impact of changing to a random‐effects analysis using a Mantel‐Haenszel OR (as the Peto OR cannot use random‐effects). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/full#CD015187-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015187-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in vertigo frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.83, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.24, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Disease‐specific health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.63, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in headache frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.87, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015187-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Calcium channel blockers versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Improvement in vertigo severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.01, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Improvement in vertigo frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.80, 3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in vertigo frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐5.94, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Improvement in headache  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.88, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Other adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [0.73, 20.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.35, 18.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Calcium channel blockers versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015187.pub2/references#CD015187-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015187.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015187-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015187-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015187-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015187-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD015187-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD015187-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015187-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015187-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015187\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015187\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015187\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015187\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015187\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015187.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015187.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015187.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015187.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015187.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718826598"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015187.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718826602"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015187.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd9c9ae08935f',t:'MTc0MDcxODgyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 